{"gene":"CCL2","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1989,"finding":"CCL2/MCP-1 was cloned and sequenced from a glioma cell line cDNA library; the precursor protein consists of a 23-residue signal peptide and a 76-residue mature protein, establishing it as a member of the inducible cytokine family with sequence similarity to mouse JE, RANTES, MIP, and TCA-3.","method":"cDNA cloning, nucleotide sequencing, amino acid sequence analysis","journal":"Biochemical and biophysical research communications / FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — primary sequence determination by cloning and sequencing, replicated across two independent labs (PMID:2923622 and PMID:2465924)","pmids":["2923622","2465924"],"is_preprint":false},{"year":1989,"finding":"CCL2/MCP-1 mRNA is induced in human peripheral blood mononuclear leukocytes by PHA, LPS, and IL-1, but not by IL-2, TNF, or IFN-γ, defining the stimulus-specific transcriptional regulation of the gene.","method":"Northern blot analysis, mRNA induction assays","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — direct mRNA induction experiments in primary human cells, foundational characterization paper","pmids":["2465924"],"is_preprint":false},{"year":1990,"finding":"Purified CCL2/MCAF specifically binds to receptors on human PBMC that are distinct from those used by IL-8, stimulates superoxide anion release and N-acetyl-β-D-glucosaminidase secretion in human monocytes, augments monocyte cytostatic activity against tumor cells, and induces in vivo local monocyte infiltration in rat ears, establishing CCL2 as both a monocyte chemoattractant and activator.","method":"Protein purification, competitive receptor-binding assays with 125I-labeled MCAF, in vitro functional assays, in vivo subcutaneous injection","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — purified protein with multiple orthogonal functional assays and in vivo validation","pmids":["2161898"],"is_preprint":false},{"year":1994,"finding":"Transcription of the human CCL2 gene is controlled by two critical cis-elements: a remote NF-κB binding site (at bp −2612 to −2603) required for IL-1β-, TNF-α-, and PMA-induced enhancer activity, and a proximal GC box (bp −64 to −59) bound by Sp1 that maintains basal transcriptional activity.","method":"5′-flanking genomic DNA sequencing, promoter-reporter assays, site-directed mutagenesis, Sp1 overexpression","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of specific promoter elements combined with reporter assays and transcription factor overexpression","pmids":["8051410"],"is_preprint":false},{"year":2001,"finding":"CCL2/MCP-1 knockout mice show significantly delayed wound re-epithelialization, reduced angiogenesis, and impaired collagen synthesis compared to wild-type, without a change in macrophage numbers in wounds, indicating CCL2 regulates the effector state of macrophages and other wound-repair cells rather than simply mediating monocyte recruitment into wounds.","method":"MCP-1 knockout mouse model, wound healing assay, histology, hydroxyproline quantification, capillary density measurement","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic knockout with multiple orthogonal phenotypic readouts","pmids":["11485904"],"is_preprint":false},{"year":2002,"finding":"Matrix metalloproteinases MMP-1 and MMP-3 cleave CCL2 between residues 4 and 5; the resulting truncated CCL2 product binds CCR2 but lacks chemoattractant activity and acts as a CCR2 antagonist, reducing inflammatory edema in vivo by >66%, revealing a proteolytic mechanism by which MMPs terminate CCL2-driven chemotaxis.","method":"Recombinant MMP cleavage assays, receptor-binding assays, transwell migration assays, in vivo carrageenan inflammation model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted cleavage with mutagenesis-equivalent synthetic analogs, functional receptor antagonism, and in vivo validation","pmids":["12149192"],"is_preprint":false},{"year":2002,"finding":"Endothelial-derived CCL2 signals through monocyte CCR2 to promote firm monocyte adhesion to inflamed endothelium under physiological flow via the β2-integrin (but not β1-integrin) pathway; MCP-1 stimulation causes rapid β2-integrin neoepitope 24 expression on monocytes, establishing a mechanistic link between endothelial CCL2 and integrin-mediated monocyte adhesion.","method":"Flow chamber assay, anti-MCP-1 neutralizing antibody, antisense oligomers, CCR2 blockade, anti-integrin antibodies, reporter mAb24 binding","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological and antibody-based blockade strategies under physiological flow conditions with integrin pathway dissection","pmids":["12388329"],"is_preprint":false},{"year":2005,"finding":"CCL2 secreted by bile duct epithelia acts in a paracrine manner on portal fibroblasts to induce their proliferation, α-smooth muscle actin redistribution (myofibroblastic transdifferentiation), loss of NTPDase2, and upregulation of α1-procollagen; these effects are mediated by a receptor on portal fibroblasts distinct from CCR2.","method":"MCP-1 blocking antibody, paracrine co-culture assays, proliferation assays, immunofluorescence for α-SMA, NTPDase2 assay, procollagen measurement","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 — antibody blockade and paracrine culture system with multiple readouts; single lab","pmids":["16282363"],"is_preprint":false},{"year":2006,"finding":"MCP-1 transgenic overexpression in adipose tissue causes macrophage infiltration, insulin resistance, and hepatic steatosis, while MCP-1 knockout reduces these phenotypes in diet-induced obese mice, and acute expression of a dominant-negative MCP-1 mutant ameliorates insulin resistance, establishing a causal role of CCL2 in obesity-induced metabolic inflammation.","method":"Transgenic mouse overexpression (aP2-MCP-1), MCP-1 homozygous knockout mice, dominant-negative mutant gene delivery, metabolic phenotyping","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — triangulated with gain-of-function transgenic, loss-of-function knockout, and acute dominant-negative rescue; multiple labs cited","pmids":["16691291"],"is_preprint":false},{"year":2007,"finding":"EBV virions induce MCP-1 secretion from human monocytes through TLR2 recognition, activating NF-κB; siRNA-mediated TLR2 knockdown significantly reduces CCL2 release, identifying TLR2 as the pattern recognition receptor upstream of CCL2 induction during EBV infection.","method":"TLR2-expressing HEK293 transfection, NF-κB-luciferase reporter assay, blocking anti-TLR2 antibodies, siRNA knockdown, ELISA","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA and antibody blockade in primary monocytes with reporter assays; single lab","pmids":["17522215"],"is_preprint":false},{"year":2008,"finding":"12(S)-HETE (a product of 12/15-lipoxygenase) increases CCL2 mRNA and protein expression in macrophages via sequential activation of PKC, p38 MAPK, and NADPH oxidase; 12/15-LO knockout mice have reduced macrophage MCP-1 expression, and transgenic overexpression of 12/15-LO increases it, defining a 12/15-LO→PKC/p38/NADPH oxidase→CCL2 regulatory axis.","method":"12(S)-HETE treatment, PKC/p38/NADPH oxidase pharmacological inhibitors, 12/15-LO transgenic and knockout mouse peritoneal macrophages, stable 12/15-LO overexpressing cell line","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological inhibitors combined with transgenic and knockout mouse models in parallel","pmids":["18296557"],"is_preprint":false},{"year":2008,"finding":"Upon MCP-1 stimulation, iPLA2β translocates to the membrane-enriched pseudopod while cPLA2α is recruited to the endoplasmic reticulum; iPLA2β regulates monocyte directionality and actin polymerization in addition to speed, whereas cPLA2α affects speed alone; antisense knockdown of either enzyme impairs monocyte migration to the peritoneum in vivo.","method":"Antisense oligodeoxynucleotides, subcellular localization imaging, transwell chemotaxis assays, actin polymerization assay, adoptive transfer in vivo migration assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — intracellular localization linked to specific functional outcomes (directionality vs. speed) with in vivo validation","pmids":["18208975"],"is_preprint":false},{"year":2009,"finding":"TNF-α activates JNK in spinal astrocytes via TNF receptor-1, leading to CCL2/MCP-1 induction; JNK inhibitors block this upregulation dose-dependently. Spinal MCP-1 subsequently activates ERK in dorsal horn neurons, enhances spontaneous EPSCs, and potentiates NMDA- and AMPA-induced currents, contributing to central sensitization and neuropathic pain.","method":"JNK inhibitors (SP600125, D-JNKI-1), cytokine array, spinal nerve ligation model, MCP-1 neutralizing antibody intrathecal injection, patch-clamp recordings in spinal cord slices","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological tools, electrophysiology, and in vivo model; mechanistic pathway from kinase to synaptic transmission defined","pmids":["19339605"],"is_preprint":false},{"year":2009,"finding":"Noradrenaline increases CCL2 expression in astrocytes via β2-adrenergic receptor–cAMP signaling activating the MCP-1 promoter; astrocyte-released MCP-1 reduces NMDA-dependent glutamate release and glutamate-mediated Ca2+ entry in neurons, protecting them from OGD-induced damage; neutralizing antibody to MCP-1 blocks the neuroprotective effect of conditioned medium from NA-treated astrocytes.","method":"β-adrenergic agonists/antagonists, cAMP analog, MCP-1 promoter–luciferase assay, MCP-1 neutralizing antibody, glutamate release assay, Ca2+ imaging, LDH assay, OGD model, transwell co-culture","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — receptor pharmacology, promoter assay, and neutralizing antibody with multiple neuronal endpoint assays","pmids":["19129402"],"is_preprint":false},{"year":2010,"finding":"Cocaine induces CCL2 expression in microglia through translocation of the sigma receptor to lipid raft microdomains, followed by sequential activation of Src, MAPKs, PI3K/Akt, and NF-κB; conditioned medium from cocaine-exposed microglia increases monocyte transmigration via CCR2, and this effect is absent in CCR2 knockout mice or with sigma receptor antagonist pretreatment.","method":"Sigma receptor antagonist, lipid raft fractionation, kinase inhibitors, CCR2 knockout mice, monocyte transmigration assay, in vivo cocaine exposure","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — pathway dissection with pharmacological inhibitors and genetic knockout, in vitro and in vivo convergent evidence","pmids":["20354174"],"is_preprint":false},{"year":2010,"finding":"Thiamine deficiency selectively induces neuronal CCL2 expression prior to microglia activation; MCP-1 from thiamine-deficient neurons activates microglia to produce cytotoxic cytokines; MCP-1 neutralizing antibody inhibits microglia activation and neuronal death; CCL2 knockout mice are resistant to thiamine deficiency-induced neurodegeneration in the thalamus.","method":"Thiamine deficiency model, neuron/microglia co-culture, MCP-1 neutralizing antibody, CCL2 knockout mice, antioxidant treatment","journal":"Brain pathology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus neutralizing antibody in both in vitro and in vivo settings","pmids":["21029241"],"is_preprint":false},{"year":2011,"finding":"CCL2 produced by tumor and stroma recruits Gr1+ inflammatory monocytes expressing CCR2 to pulmonary metastases; these inflammatory monocytes promote tumor cell extravasation via monocyte-derived VEGF; inhibition of CCL2-CCR2 signaling blocks monocyte recruitment and inhibits metastasis in vivo, defining a CCL2→CCR2→VEGF→extravasation mechanistic axis in breast cancer metastasis.","method":"CCL2-knockout mice, CCL2 antibody blockade, bone marrow chimeras, monocyte depletion, VEGF measurement, in vivo metastasis model","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and antibody-based loss-of-function approaches with mechanistic VEGF link; high-impact publication","pmids":["21654748"],"is_preprint":false},{"year":2011,"finding":"Reactive nitrogen species within the tumor microenvironment nitrate CCL2, and this nitrated form fails to recruit T cells into the tumor core, trapping them in the surrounding stroma; drugs that inhibit CCL2 nitration restore CTL invasion, revealing RNS-mediated post-translational modification of CCL2 as a tumor immune evasion mechanism.","method":"RNS detection in tumor microenvironment, chemokine nitration biochemistry, T cell trafficking assays, pharmacological inhibition of CCL2 modification in mouse and human tumors","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — novel post-translational modification (nitration) with functional consequence on leukocyte trafficking, validated in mouse and human tumors","pmids":["21930770"],"is_preprint":false},{"year":2012,"finding":"CCL2 deficiency in ApcMin/+ mice reduces polyp number (especially large polyps) and decreases F4/80+ macrophages in polyp and intestinal tissue, shifts cytokine balance (reduces IL-1β, IL-6, increases SOCS1), increases cytotoxic T lymphocytes and decreases regulatory T cells, establishing CCL2 as a mediator of tumor-associated macrophage recruitment and immune regulation in intestinal tumorigenesis.","method":"MCP-1 knockout in ApcMin/+ genetic background, histology, immunohistochemistry, cytokine mRNA quantification","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic knockout with multiple immune and tumor endpoints; single lab","pmids":["23019193"],"is_preprint":false},{"year":2012,"finding":"MCP-1 deficiency in mice leads to elevated bone mass due to reduced osteoclast number and activity; MCP-1-null osteoclast precursors show reduced c-Fms and RANK receptor levels, impaired actin ring formation, and reduced activation of ERK, Akt, Rac1, and Rho upon M-CSF stimulation, placing CCL2 upstream of M-CSF signaling and cytoskeletal organization in osteoclastogenesis.","method":"MCP-1 knockout mice, bone densitometry, serum CTX-1 and TRACP 5b, in vitro osteoclastogenesis, actin ring staining, Western blot for signaling molecules","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with mechanistic signaling readouts; single lab","pmids":["21678414"],"is_preprint":false},{"year":2013,"finding":"IκBζ, an atypical IκB family member and NF-κB transcriptional coactivator, directly binds the proximal promoter of the Ccl2 gene (shown by ChIP) and is required for LPS- and peptidoglycan-induced CCL2 secretion in macrophages; IκBζ-deficient mice show impaired CCL2 secretion and monocyte infiltration in peritonitis; IκBζ binding enables transcription-enhancing H3K4 trimethylation at the Ccl2 promoter.","method":"IκBζ-knockout macrophages, chromatin immunoprecipitation (ChIP), histone methylation assay, peritonitis model, ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP demonstrates direct promoter occupancy, genetic knockout, epigenetic mark identified, in vivo validation","pmids":["23547114"],"is_preprint":false},{"year":2013,"finding":"OxLDL binds CCL2 through oxidized phospholipids, and basic residues Arg-18 and Lys-19 in CCL2 are required for this interaction (shown by Arg18Ala/Lys19Ala mutant that fails to bind OxLDL); lipoprotein(a) in human plasma also binds CCL2 via oxidized phospholipids, and Lp(a)-associated endogenous MCP-1 retains monocyte-recruiting activity.","method":"OxLDL binding assay, site-directed mutagenesis (R18A/K19A), monoclonal antibody E06 blocking, human plasma Lp(a) capture, monocyte migration assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis identifies specific binding residues, confirmed in human plasma with functional monocyte migration readout","pmids":["23667177"],"is_preprint":false},{"year":2014,"finding":"CCL2 produced by tumor-derived macrophages/microglia recruits both CCR4+ regulatory T cells and CCR2+Ly-6C+ monocytic MDSCs into gliomas; glioma-derived CCL20 and osteoprotegerin induce CCL2 production from macrophages/microglia; in mixed bone marrow chimera assays, CCR4-deficient Tregs and CCR2-deficient monocytic MDSCs fail to accumulate in gliomas.","method":"CCL2-deficient mice, mixed bone marrow chimeras, CCR4/CCR2 knockout cells, small-molecule CCR4 antagonist, survival analysis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout and chimera experiments combined with pharmacological CCR4 blockade; mechanistic induction pathway identified","pmids":["27530322"],"is_preprint":false},{"year":2014,"finding":"CCL2 promotes macrophage M2 polarization: CCL2 enhances LPS-induced IL-10 production, while CCL2 blockade increases M1 markers and reduces M2 markers in human macrophages; Ccr2-deficient murine macrophages display M1-skewed polarization with higher TNF-α and IL-6 in response to LPS; activin A controls differential CCL2/CCR2 expression, inhibiting CCL2 acquisition by M-CSF-polarized macrophages.","method":"CCL2 blocking antibody, Ccr2-knockout bone marrow-derived macrophages, gene expression profiling, cytokine ELISA, activin A treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — antibody blockade plus genetic knockout with transcriptomic profiling; replicated in human and murine systems","pmids":["24639350"],"is_preprint":false},{"year":2015,"finding":"ATF4, an ER stress-inducible transcription factor, is a key regulator of CCL2 production in microvascular endothelial cells; ATF4 overexpression increases CCL2 secretion and promotes monocyte adhesion, while ATF4-deficient endothelial cells and ATF4 heterozygous knockout retinas show markedly attenuated LPS-induced CCL2; ATF4 acts upstream of NF-κB, p38, and JNK phosphorylation to drive CCL2 expression.","method":"ATF4 knockout mice, adenoviral ATF4 overexpression/dominant-negative, LPS stimulation, pharmacological inhibition of NF-κB/p38/JNK, monocyte adhesion assay, intravitreal injection","journal":"Journal of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and adenoviral gain/loss-of-function with signaling pathway inhibitors; single lab","pmids":["25914608"],"is_preprint":false},{"year":2016,"finding":"During mesenchymal stromal cell senescence, MCP-1 is secreted as a dominant SASP component and reinforces senescence via CCR2-activated ROS-p38-MAPK-p53/p21 cascade in autocrine/paracrine fashion; activated p53 further increases MCP-1 secretion, forming a feed-forward loop; BMI1 epigenetically represses CCL2 expression by binding its regulatory elements and maintaining H2AK119Ub; BMI1 decline during senescence leads to loss of this mark and CCL2 derepression.","method":"CCR2 knockdown, p38/MAPK/p53 inhibitors, ChIP for BMI1 and H2AK119Ub, ROS measurement, SASP profiling by ELISA","journal":"Antioxidants & redox signaling","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP identifies specific epigenetic regulator and histone mark, combined with siRNA knockdown and pharmacological pathway dissection","pmids":["26573462"],"is_preprint":false},{"year":2019,"finding":"CCL2/CCR2 signaling shapes macrophage behavior beyond chemotaxis, including promoting survival of CD11b+ monocytes via upregulation of cFLIPL, Bcl-2, and Bcl-XL and inhibition of caspase-8 cleavage; CCL2 induces autophagy hyperactivation and M2-type (CD206+) macrophage polarization; blockade of autophagic degradation reverses CCL2-induced M2 polarization.","method":"CCL2 stimulation of primary human CD11b+ cells, Western blot for apoptotic proteins, caspase-8 activity assays, flow cytometry for CD206, autophagy inhibitor treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic readouts in primary human cells; single lab","pmids":["19833726"],"is_preprint":false},{"year":2023,"finding":"Hepatocyte-specific CCL2 expression is driven by Notch signaling through an evolutionarily conserved RBPjκ binding site in the Ccl2 promoter; hepatocyte-specific Ccl2 knockout reduces liver monocyte-derived macrophage infiltration and fibrosis in NASH, while forced hepatocyte MCP-1 expression produces the opposite phenotype; the effect is rescued by CCR2 inhibitor treatment.","method":"Hepatocyte-specific Ccl2 knockout mice, Notch gain-of-function mice, Ccl2 promoter analysis for RBPjκ binding site, CCR2 inhibitor treatment, liver histology and fibrosis quantification","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 — tissue-specific knockout plus gain-of-function with promoter mechanistic analysis; pharmacological rescue confirms pathway","pmids":["36752206"],"is_preprint":false}],"current_model":"CCL2/MCP-1 is a secreted CC chemokine (76-residue mature protein with 23-residue signal peptide, gene regulated by NF-κB and Sp1 at the promoter and additionally by transcriptional coactivators IκBζ, ATF4, p53, and epigenetic repressor BMI1) that acts as a potent, specific monocyte/macrophage chemoattractant and activator by binding its primary receptor CCR2 (a Gαi-coupled GPCR), triggering Ca2+ flux, chemotaxis via iPLA2β-regulated actin polarization, β2-integrin-mediated firm adhesion to endothelium, and downstream PI3K/Akt, Src/MAPK, and NF-κB signaling; beyond chemotaxis, CCL2-CCR2 signaling promotes M2 macrophage polarization via caspase-8 inhibition and autophagy, drives myofibroblast transdifferentiation, regulates osteoclast actin ring formation and M-CSF signaling, mediates cardiomyocyte apoptosis through MCPIP1 and CaSR, induces excitatory synaptic transmission in spinal neurons contributing to neuropathic pain, and can be post-translationally inactivated by MMP cleavage (between residues 4–5, generating a CCR2 antagonist) or by RNS-mediated nitration that abolishes leukocyte recruitment."},"narrative":{"teleology":[{"year":1989,"claim":"Molecular cloning of CCL2 from two independent laboratories established its identity as a 99-residue precursor (23-aa signal peptide + 76-aa mature protein) belonging to the CC chemokine family, providing the sequence foundation for all subsequent structure–function work.","evidence":"cDNA cloning and sequencing from glioma cell line and stimulated PBMCs","pmids":["2923622","2465924"],"confidence":"High","gaps":["Three-dimensional structure not yet determined at this stage","Receptor identity unknown","Post-translational modifications uncharacterized"]},{"year":1990,"claim":"Purified CCL2 was shown to bind a specific receptor on monocytes distinct from IL-8 receptors and to activate superoxide release, lysosomal enzyme secretion, tumoricidal activity, and in vivo monocyte infiltration, establishing it as both a chemoattractant and a monocyte activator.","evidence":"125I-labeled MCAF competitive binding, functional assays on purified human monocytes, in vivo rat ear injection","pmids":["2161898"],"confidence":"High","gaps":["Receptor molecular identity not yet cloned","Intracellular signaling cascade undefined","Redundancy with other CC chemokines not addressed"]},{"year":1994,"claim":"Promoter dissection resolved how CCL2 transcription is controlled, identifying a distal NF-κB site required for cytokine-induced expression and a proximal Sp1 GC-box for basal activity, explaining how diverse inflammatory stimuli converge on CCL2 induction.","evidence":"5′-flanking sequence analysis, promoter-reporter mutagenesis, Sp1 overexpression","pmids":["8051410"],"confidence":"High","gaps":["Chromatin-level regulation and epigenetic marks not addressed","Cell-type-specific promoter usage not explored","Role of enhancer elements beyond the distal NF-κB site unknown"]},{"year":2001,"claim":"CCL2 knockout mice revealed an unexpected role beyond monocyte recruitment: impaired wound re-epithelialization, angiogenesis, and collagen synthesis without altered macrophage numbers, demonstrating that CCL2 regulates macrophage effector function in tissue repair.","evidence":"MCP-1 knockout mice, wound healing assay, histology, hydroxyproline and capillary density quantification","pmids":["11485904"],"confidence":"High","gaps":["Downstream effector signals in wound macrophages not identified","Whether CCR2-independent receptors contribute not tested","Compensatory chemokine upregulation not assessed"]},{"year":2002,"claim":"Two advances defined how CCL2 signaling is executed and terminated: endothelial CCL2 was shown to trigger β2-integrin activation and firm monocyte adhesion under flow via CCR2, while MMP-1/MMP-3 cleavage between residues 4–5 was found to generate a truncated CCR2 antagonist that blocks chemotaxis and reduces inflammation in vivo.","evidence":"Flow chamber with anti-integrin/anti-CCR2 blocking antibodies; recombinant MMP cleavage with receptor binding and in vivo carrageenan model","pmids":["12388329","12149192"],"confidence":"High","gaps":["Structural basis of MMP cleavage site selectivity not resolved","Kinetics of MMP-mediated inactivation in tissue contexts unknown","Whether other proteases generate similar antagonistic fragments not tested"]},{"year":2006,"claim":"Gain-of-function (transgenic), loss-of-function (knockout), and dominant-negative approaches in mice causally linked CCL2 to adipose tissue macrophage infiltration, insulin resistance, and hepatic steatosis, establishing CCL2 as a key mediator of obesity-associated metabolic inflammation.","evidence":"aP2-MCP-1 transgenic mice, MCP-1 knockout mice, dominant-negative mutant gene delivery, metabolic phenotyping","pmids":["16691291"],"confidence":"High","gaps":["Relative contributions of adipocyte- vs. macrophage-derived CCL2 not separated","Direct hepatic signaling targets of CCL2 in steatosis undefined","Human genetic evidence for CCL2 in metabolic syndrome not provided"]},{"year":2008,"claim":"iPLA2β and cPLA2α were identified as spatially segregated effectors downstream of CCL2-induced chemotaxis: iPLA2β localizes to the pseudopod and controls directionality and actin polymerization, while cPLA2α at the ER controls migration speed, explaining how a single chemokine generates multi-component migratory responses.","evidence":"Antisense knockdown, subcellular localization imaging, actin polymerization assay, adoptive transfer migration in vivo","pmids":["18208975"],"confidence":"High","gaps":["Lipid products mediating each PLA2 branch not identified","How CCR2 differentially activates iPLA2β vs. cPLA2α unknown","Whether this mechanism applies to other CC chemokine receptors untested"]},{"year":2009,"claim":"CCL2 was placed in neural circuitry: TNF-α/JNK induces astrocytic CCL2, which activates ERK in spinal dorsal horn neurons, enhances excitatory postsynaptic currents, and potentiates NMDA/AMPA responses, defining a glial-to-neuronal CCL2 signaling axis in neuropathic pain central sensitization.","evidence":"JNK inhibitors, spinal nerve ligation model, intrathecal MCP-1 neutralizing antibody, patch-clamp electrophysiology","pmids":["19339605"],"confidence":"High","gaps":["Direct neuronal receptor mediating synaptic potentiation not confirmed as CCR2 vs. alternative","Whether astrocytic CCL2 acts presynaptically or postsynaptically not resolved","Contribution relative to other pain chemokines not quantified"]},{"year":2011,"claim":"CCL2 was shown to be subject to reactive nitrogen species–mediated nitration in the tumor microenvironment, which abolishes T-cell recruitment into tumor cores; pharmacological inhibition of nitration restored CTL infiltration, identifying post-translational nitration as a tumor immune evasion mechanism.","evidence":"RNS detection, chemokine nitration biochemistry, T-cell trafficking assays, pharmacological inhibition in mouse and human tumors","pmids":["21930770"],"confidence":"High","gaps":["Specific tyrosine residue(s) nitrated not mapped","Whether nitrated CCL2 acquires gain-of-function activities unknown","Generalizability to other chemokines in the tumor microenvironment not tested"]},{"year":2011,"claim":"CCL2 was causally linked to breast cancer metastasis: tumor/stromal CCL2 recruits CCR2+Ly-6C+ inflammatory monocytes to pulmonary metastatic sites, and these monocytes promote tumor cell extravasation through VEGF production, defining a CCL2→CCR2→VEGF→extravasation metastatic axis.","evidence":"CCL2-knockout mice, antibody blockade, bone marrow chimeras, monocyte depletion, in vivo metastasis model","pmids":["21654748"],"confidence":"High","gaps":["Whether tumor cells co-opt additional CCL2-independent monocyte recruitment pathways not assessed","Precise mechanism by which monocyte-derived VEGF promotes extravasation not defined","Clinical relevance of CCL2 blockade withdrawal (rebound effect) not addressed"]},{"year":2013,"claim":"IκBζ was identified as a direct transcriptional coactivator of Ccl2 by ChIP, linking NF-κB to epigenetic activation: IκBζ binding enables H3K4 trimethylation at the Ccl2 promoter, and IκBζ-deficient macrophages show impaired CCL2 secretion and monocyte recruitment in vivo.","evidence":"IκBζ-knockout macrophages, ChIP for IκBζ and H3K4me3, peritonitis model, ELISA","pmids":["23547114"],"confidence":"High","gaps":["Methyltransferase recruited by IκBζ not identified","Whether IκBζ cooperates with Sp1 at the proximal promoter untested","Kinetics of epigenetic mark deposition relative to transcription initiation unknown"]},{"year":2016,"claim":"A senescence-associated feed-forward loop was defined: secreted CCL2 activates CCR2→ROS→p38→p53/p21 in mesenchymal stromal cells, and activated p53 further increases CCL2 transcription; BMI1 was identified as an epigenetic repressor that silences CCL2 via H2AK119Ub, with BMI1 decline during senescence derepressing CCL2.","evidence":"CCR2 knockdown, p38/MAPK/p53 inhibitors, ChIP for BMI1 and H2AK119Ub, ROS measurement","pmids":["26573462"],"confidence":"High","gaps":["Whether BMI1 loss is a cause or consequence of senescence initiation not fully resolved","Quantitative contribution of autocrine vs. paracrine CCL2 loop not measured","Whether this loop operates in epithelial senescence unknown"]},{"year":2023,"claim":"Hepatocyte-specific CCL2 was found to be transcriptionally driven by Notch signaling through a conserved RBPJκ binding site in the Ccl2 promoter; hepatocyte-specific Ccl2 knockout reduced monocyte-derived macrophage infiltration and liver fibrosis in NASH, directly linking cell-type-specific CCL2 production to metabolic liver disease.","evidence":"Hepatocyte-specific Ccl2 knockout, Notch gain-of-function mice, RBPJκ promoter analysis, CCR2 inhibitor rescue, liver fibrosis quantification","pmids":["36752206"],"confidence":"High","gaps":["Whether Notch-driven CCL2 operates in other parenchymal cell types unknown","Interaction between RBPJκ and NF-κB/Sp1 on the CCL2 promoter not characterized","Therapeutic window for CCR2 inhibition in human NASH not established"]},{"year":null,"claim":"Despite extensive characterization, the full structural basis of CCL2–CCR2 activation (including the role of CCL2 oligomerization on GAGs in vivo), the identity of the non-CCR2 receptor mediating fibroblast transdifferentiation, and the quantitative contribution of individual cell-type-specific CCL2 sources across disease contexts remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of the CCL2–CCR2 signaling complex in a lipid bilayer","Non-CCR2 receptor on fibroblasts not molecularly identified","Systems-level quantification of tissue-specific CCL2 sources in vivo lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,6,16]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,5,7,8,16,25]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,6,11,16,17,18,22,23,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,13,14,25,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,16,17,18,27]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,20,25,27]}],"complexes":[],"partners":["CCR2","MMP1","MMP3","NFKB1","SP1","NFKBIZ","BMI1","ATF4"],"other_free_text":[]},"mechanistic_narrative":"CCL2 (MCP-1) is a secreted CC chemokine that functions as a principal monocyte/macrophage chemoattractant and activator, orchestrating innate immune cell recruitment in inflammation, tissue repair, metabolic disease, neurodegeneration, and tumor progression. The mature 76-residue protein signals primarily through the Gαi-coupled receptor CCR2 to trigger β2-integrin-dependent firm adhesion to endothelium, iPLA2β-regulated actin polarization and directional migration, and downstream PI3K/Akt, Src/MAPK, and NF-κB cascades; beyond chemotaxis, CCL2–CCR2 signaling promotes M2 macrophage polarization via caspase-8 inhibition and autophagy, drives myofibroblast transdifferentiation, modulates osteoclastogenesis, and enhances excitatory synaptic transmission in spinal neurons [PMID:2161898, PMID:12388329, PMID:18208975, PMID:19833726, PMID:19339605, PMID:21678414]. Transcription is controlled by an NF-κB distal enhancer and a proximal Sp1 site, with additional regulation by IκBζ-dependent H3K4 trimethylation, ATF4, BMI1-mediated H2AK119Ub repression, and Notch/RBPJκ in hepatocytes [PMID:8051410, PMID:23547114, PMID:26573462, PMID:36752206]. CCL2 activity is terminated post-translationally by MMP-1/MMP-3 cleavage between residues 4–5, generating a CCR2 antagonist, or by reactive nitrogen species–mediated nitration that abolishes leukocyte recruitment [PMID:12149192, PMID:21930770]."},"prefetch_data":{"uniprot":{"accession":"P13500","full_name":"C-C motif chemokine 2","aliases":["HC11","Monocyte chemoattractant protein 1","Monocyte chemotactic and activating factor","MCAF","Monocyte chemotactic protein 1","MCP-1","Monocyte secretory protein JE","Small-inducible cytokine A2"],"length_aa":99,"mass_kda":11.0,"function":"Acts as a ligand for C-C chemokine receptor CCR2 (PubMed:10529171, PubMed:10587439, PubMed:9837883). Signals through binding and activation of CCR2 and induces a strong chemotactic response and mobilization of intracellular calcium ions (PubMed:10587439, PubMed:9837883). Exhibits a chemotactic activity for monocytes and basophils but not neutrophils or eosinophils (PubMed:8195247, PubMed:8627182, PubMed:9792674). May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis (PubMed:8107690)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P13500/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL2","total_profiled":1310},"omim":[{"mim_id":"621526","title":"GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE-LIKE PROTEIN; QPCTL","url":"https://www.omim.org/entry/621526"},{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"619991","title":"LIVER DISEASE, SEVERE CONGENITAL; SCOLIV","url":"https://www.omim.org/entry/619991"},{"mim_id":"616761","title":"SUSHI DOMAIN-CONTAINING PROTEIN 6; SUSD6","url":"https://www.omim.org/entry/616761"},{"mim_id":"616709","title":"ALPHA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; A4GNT","url":"https://www.omim.org/entry/616709"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"urinary bladder","ntpm":701.0}],"url":"https://www.proteinatlas.org/search/CCL2"},"hgnc":{"alias_symbol":["MCP1","MCP-1","MCAF","SMC-CF","GDCF-2","HC11","MGC9434"],"prev_symbol":["SCYA2"]},"alphafold":{"accession":"P13500","domains":[{"cath_id":"2.40.50.40","chopping":"34-99","consensus_level":"medium","plddt":93.1655,"start":34,"end":99}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13500","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13500-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13500-F1-predicted_aligned_error_v6.png","plddt_mean":86.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL2","jax_strain_url":"https://www.jax.org/strain/search?query=CCL2"},"sequence":{"accession":"P13500","fasta_url":"https://rest.uniprot.org/uniprotkb/P13500.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13500/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13500"}},"corpus_meta":[{"pmid":"19441883","id":"PMC_19441883","title":"Monocyte chemoattractant protein-1 (MCP-1): an overview.","date":"2009","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/19441883","citation_count":3053,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16691291","id":"PMC_16691291","title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16691291","citation_count":2100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34233864","id":"PMC_34233864","title":"MCP-1: Function, regulation, and involvement in disease.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34233864","citation_count":676,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2186747","id":"PMC_2186747","title":"Human monocyte chemoattractant protein-1 (MCP-1).","date":"1990","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/2186747","citation_count":580,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19339605","id":"PMC_19339605","title":"JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19339605","citation_count":490,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18190912","id":"PMC_18190912","title":"Increased MCP-1 and microglia in various regions of the human alcoholic brain.","date":"2007","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18190912","citation_count":424,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20681057","id":"PMC_20681057","title":"The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20681057","citation_count":337,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12096201","id":"PMC_12096201","title":"Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.","date":"2002","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/12096201","citation_count":278,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2923622","id":"PMC_2923622","title":"Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF).","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2923622","citation_count":269,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11485904","id":"PMC_11485904","title":"Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11485904","citation_count":261,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"13129912","id":"PMC_13129912","title":"Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/13129912","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8616572","id":"PMC_8616572","title":"Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients.","date":"1996","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8616572","citation_count":257,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2161898","id":"PMC_2161898","title":"Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line.","date":"1990","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2161898","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19566488","id":"PMC_19566488","title":"Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19566488","citation_count":241,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29375123","id":"PMC_29375123","title":"The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29375123","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12851645","id":"PMC_12851645","title":"Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung.","date":"2003","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/12851645","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24618995","id":"PMC_24618995","title":"Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage response.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24618995","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9916917","id":"PMC_9916917","title":"Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9916917","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10515417","id":"PMC_10515417","title":"Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases.","date":"1999","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10515417","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17625118","id":"PMC_17625118","title":"Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.","date":"2007","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/17625118","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15144891","id":"PMC_15144891","title":"Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15144891","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24862889","id":"PMC_24862889","title":"Impact of MCP-1 in atherosclerosis.","date":"2014","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/24862889","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10469372","id":"PMC_10469372","title":"Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.","date":"1999","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10469372","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8345212","id":"PMC_8345212","title":"MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions.","date":"1993","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8345212","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19129402","id":"PMC_19129402","title":"Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19129402","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10489845","id":"PMC_10489845","title":"Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics.","date":"1999","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/10489845","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17522215","id":"PMC_17522215","title":"Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2.","date":"2007","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/17522215","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9763529","id":"PMC_9763529","title":"Estradiol suppresses MCP-1 expression In vivo : implications for atherosclerosis.","date":"1998","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9763529","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20354174","id":"PMC_20354174","title":"Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20354174","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16282363","id":"PMC_16282363","title":"Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts.","date":"2005","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16282363","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16106105","id":"PMC_16106105","title":"Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction.","date":"2005","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/16106105","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11751168","id":"PMC_11751168","title":"MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat.","date":"2002","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11751168","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21029241","id":"PMC_21029241","title":"Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism.","date":"2010","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/21029241","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11149670","id":"PMC_11149670","title":"Neuronal MCP-1 expression in response to remote nerve injury.","date":"2001","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11149670","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23019193","id":"PMC_23019193","title":"Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1.","date":"2012","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23019193","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26573462","id":"PMC_26573462","title":"Senescence-Associated MCP-1 Secretion Is Dependent on a Decline in BMI1 in Human Mesenchymal Stromal Cells.","date":"2016","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/26573462","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18442784","id":"PMC_18442784","title":"Role of MCP-1 in endotoxemia and sepsis.","date":"2008","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18442784","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19617401","id":"PMC_19617401","title":"MCP-1 antibody treatment enhances damage and impedes repair of the alveolar epithelium in influenza pneumonitis.","date":"2009","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19617401","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23547114","id":"PMC_23547114","title":"IκBζ is a transcriptional key regulator of CCL2/MCP-1.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23547114","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23667177","id":"PMC_23667177","title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23667177","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22473371","id":"PMC_22473371","title":"Obese Mexican American children have elevated MCP-1, TNF-α, monocyte concentration, and dyslipidemia.","date":"2012","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/22473371","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10905466","id":"PMC_10905466","title":"Increased expression of chemokines (MCP-1, MIP-1alpha, RANTES) after peripheral nerve transection.","date":"2000","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/10905466","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27069796","id":"PMC_27069796","title":"Aging and serum MCP-1 are associated with gut microbiome composition in a murine model.","date":"2016","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/27069796","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12556365","id":"PMC_12556365","title":"Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms.","date":"2003","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12556365","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9620670","id":"PMC_9620670","title":"Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9620670","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17991428","id":"PMC_17991428","title":"Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17991428","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8301205","id":"PMC_8301205","title":"Gamma interferon stimulates monocyte chemotactic protein (MCP-1) in human mesangial cells.","date":"1994","source":"The Journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8301205","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16275896","id":"PMC_16275896","title":"Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16275896","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18296557","id":"PMC_18296557","title":"Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages.","date":"2008","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18296557","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9649190","id":"PMC_9649190","title":"Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES.","date":"1998","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9649190","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21701898","id":"PMC_21701898","title":"Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes.","date":"2011","source":"European journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21701898","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18208975","id":"PMC_18208975","title":"iPLA2beta: front and center in human monocyte chemotaxis to MCP-1.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18208975","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12388329","id":"PMC_12388329","title":"Role of endothelial MCP-1 in monocyte adhesion to inflamed human endothelium under physiological flow.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388329","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15259906","id":"PMC_15259906","title":"Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.","date":"2004","source":"Antiviral therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15259906","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30472461","id":"PMC_30472461","title":"Role of MCP-1 and CCR2 in alcohol neurotoxicity.","date":"2018","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/30472461","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38239353","id":"PMC_38239353","title":"Role of MCP-1 as an inflammatory biomarker in nephropathy.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38239353","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36752206","id":"PMC_36752206","title":"Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36752206","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21678414","id":"PMC_21678414","title":"Absence of MCP-1 leads to elevated bone mass via impaired actin ring formation.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21678414","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25914608","id":"PMC_25914608","title":"ATF4 is a novel regulator of MCP-1 in microvascular endothelial cells.","date":"2015","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25914608","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24222114","id":"PMC_24222114","title":"MCP-1 promotes invasion and adhesion of human ovarian cancer cells.","date":"2013","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24222114","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24881026","id":"PMC_24881026","title":"The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation.","date":"2014","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/24881026","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20406462","id":"PMC_20406462","title":"Regulation of MCP-1 chemokine transcription by p53.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20406462","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16857270","id":"PMC_16857270","title":"MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS).","date":"2006","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/16857270","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16488443","id":"PMC_16488443","title":"MCP-1 parallels inflammatory and regenerative responses in ischemic muscle.","date":"2006","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/16488443","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21529952","id":"PMC_21529952","title":"Endogenous MCP-1 promotes lung inflammation induced by LPS and LTA.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21529952","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19951731","id":"PMC_19951731","title":"Regulating MCP-1 diffusion in affinity hydrogels for enhancing immuno-isolation.","date":"2009","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/19951731","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25555372","id":"PMC_25555372","title":"MCP-1 stimulates spinal microglia via PI3K/Akt pathway in bone cancer pain.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/25555372","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30147653","id":"PMC_30147653","title":"miR-374a Regulates Inflammatory Response in Diabetic Nephropathy by Targeting MCP-1 Expression.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30147653","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9847345","id":"PMC_9847345","title":"Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9847345","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27278779","id":"PMC_27278779","title":"Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis.","date":"2017","source":"Zeitschrift fur Rheumatologie","url":"https://pubmed.ncbi.nlm.nih.gov/27278779","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18270300","id":"PMC_18270300","title":"Insulin regulation of MCP-1 in human adipose tissue of obese and lean women.","date":"2008","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18270300","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12787135","id":"PMC_12787135","title":"17Beta-estradiol inhibits MCP-1 production in human keratinocytes.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12787135","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21496183","id":"PMC_21496183","title":"IL-8 and MCP-1 induced by excessive orthodontic force mediates odontoclastogenesis in periodontal tissues.","date":"2010","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21496183","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14962280","id":"PMC_14962280","title":"Adult porcine islets produce MCP-1 and recruit human monocytes in vitro.","date":"2004","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/14962280","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16455275","id":"PMC_16455275","title":"Modulation of MCP-1 and iNOS by 50-Hz sinusoidal electromagnetic field.","date":"2006","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16455275","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17977946","id":"PMC_17977946","title":"MCP-1 targeting inhibits muscularis macrophage recruitment and intestinal smooth muscle dysfunction in colonic inflammation.","date":"2007","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17977946","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12372783","id":"PMC_12372783","title":"Existence of a regulatory loop between MCP-1 and TGF-beta in glomerular immune injury.","date":"2002","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12372783","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19215923","id":"PMC_19215923","title":"Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19215923","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24886588","id":"PMC_24886588","title":"Sulfur compounds block MCP-1 production by Mycoplasma fermentans-infected macrophages through NF-κB inhibition.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24886588","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25531096","id":"PMC_25531096","title":"Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.","date":"2014","source":"Nephron","url":"https://pubmed.ncbi.nlm.nih.gov/25531096","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19588527","id":"PMC_19588527","title":"Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/19588527","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17307812","id":"PMC_17307812","title":"Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-dependent mechanism.","date":"2007","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17307812","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22750227","id":"PMC_22750227","title":"RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis.","date":"2012","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22750227","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20385066","id":"PMC_20385066","title":"Impact of RANTES, MCP-1 and IL-8 in mast cells.","date":"2010","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/20385066","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16164630","id":"PMC_16164630","title":"Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.","date":"2005","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16164630","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23187120","id":"PMC_23187120","title":"Spinal MCP-1 contributes to the development of morphine antinociceptive tolerance in rats.","date":"2012","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23187120","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32218781","id":"PMC_32218781","title":"Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32218781","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26014148","id":"PMC_26014148","title":"Role of MCP-1 in alcohol-induced aggressiveness of colorectal cancer cells.","date":"2015","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26014148","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29304171","id":"PMC_29304171","title":"MCP-1, KC-like and IL-8 as critical mediators of pathogenesis caused by Babesia canis.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29304171","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11750041","id":"PMC_11750041","title":"Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee.","date":"2002","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/11750041","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34868363","id":"PMC_34868363","title":"MCP-1 targeting: Shutting off an engine for tumor development.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34868363","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25688817","id":"PMC_25688817","title":"Exercise in pregnancy does not alter gestational weight gain, MCP-1 or leptin in obese women.","date":"2015","source":"The Australian & New Zealand journal of obstetrics & gynaecology","url":"https://pubmed.ncbi.nlm.nih.gov/25688817","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20855682","id":"PMC_20855682","title":"Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome.","date":"2010","source":"Archives of otolaryngology--head & neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/20855682","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25595582","id":"PMC_25595582","title":"Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis.","date":"2015","source":"Pathophysiology : the official journal of the International Society for Pathophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/25595582","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10547276","id":"PMC_10547276","title":"Increased monocyte MCP-1 production in acute alcoholic hepatitis.","date":"1999","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/10547276","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20571857","id":"PMC_20571857","title":"MCP-1 promotes mural cell recruitment during angiogenesis in the aortic ring model.","date":"2010","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20571857","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10576162","id":"PMC_10576162","title":"Synthesis and secretion of MCP-1 by dental follicle cells--implications for tooth eruption.","date":"1999","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/10576162","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16968890","id":"PMC_16968890","title":"Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease.","date":"2006","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16968890","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31774703","id":"PMC_31774703","title":"MCP-1 mediates ischemia-reperfusion-induced cardiomyocyte apoptosis via MCPIP1 and CaSR.","date":"2019","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31774703","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17655880","id":"PMC_17655880","title":"D-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs.","date":"2007","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17655880","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21654748","id":"PMC_21654748","title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21654748","citation_count":2355,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2465924","id":"PMC_2465924","title":"Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE.","date":"1989","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/2465924","citation_count":593,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21930770","id":"PMC_21930770","title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21930770","citation_count":523,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27530322","id":"PMC_27530322","title":"CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27530322","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31921102","id":"PMC_31921102","title":"More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31921102","citation_count":518,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9501225","id":"PMC_9501225","title":"Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9501225","citation_count":483,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18439751","id":"PMC_18439751","title":"The inflammatory chemokines CCL2 and CCL5 in breast cancer.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18439751","citation_count":481,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8051410","id":"PMC_8051410","title":"NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8051410","citation_count":471,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19833726","id":"PMC_19833726","title":"CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19833726","citation_count":463,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12149192","id":"PMC_12149192","title":"Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12149192","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8642344","id":"PMC_8642344","title":"Cloning, expression, and characterization of the human eosinophil eotaxin receptor.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642344","citation_count":441,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18678243","id":"PMC_18678243","title":"Peripheral cytokines profile in Parkinson's disease.","date":"2008","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18678243","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26885690","id":"PMC_26885690","title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26885690","citation_count":413,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10925302","id":"PMC_10925302","title":"Human galectin-3 is a novel chemoattractant for monocytes and macrophages.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10925302","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24639350","id":"PMC_24639350","title":"CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24639350","citation_count":408,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19904283","id":"PMC_19904283","title":"Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.","date":"2009","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19904283","citation_count":370,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18272603","id":"PMC_18272603","title":"MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18272603","citation_count":357,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32103760","id":"PMC_32103760","title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32103760","citation_count":357,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11350939","id":"PMC_11350939","title":"Chemokine receptor homo- or heterodimerization activates distinct signaling pathways.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11350939","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15919935","id":"PMC_15919935","title":"Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis.","date":"2005","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/15919935","citation_count":347,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22472119","id":"PMC_22472119","title":"CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22472119","citation_count":343,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16436595","id":"PMC_16436595","title":"CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16436595","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30237493","id":"PMC_30237493","title":"LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30237493","citation_count":336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9182688","id":"PMC_9182688","title":"Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9182688","citation_count":329,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52052,"output_tokens":7543,"usd":0.134651},"stage2":{"model":"claude-opus-4-6","input_tokens":11388,"output_tokens":3918,"usd":0.232335},"total_usd":0.756388,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66456,"output_tokens":7524,"usd":0.156114},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11580,"output_tokens":3905,"usd":0.233288}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CCL2/MCP-1 was cloned and sequenced; the cDNA encodes a precursor of 99 amino acids (23-aa signal peptide + 76-aa mature protein), and the mature protein shows 25-55% homology with other members of the inducible cytokine (chemokine) family including JE, LD78, RANTES, and TCA-3, placing it within the CC chemokine subfamily.\",\n      \"method\": \"cDNA cloning and sequencing from human peripheral blood mononuclear cell-derived mRNA\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning/sequencing paper, foundational structural characterization\",\n      \"pmids\": [\"2923622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Purified MCP-1 (MCAF) specifically binds to receptors on human peripheral blood mononuclear cells (PBMCs) distinct from IL-8 receptors, stimulates superoxide anion production, N-acetyl-β-D-glucosaminidase release, and cytostatic activity in monocytes, and induces in vivo local monocyte infiltration when injected subcutaneously into rat ears, establishing it as both a chemoattractant and monocyte activator acting through specific receptors.\",\n      \"method\": \"Protein purification from fibrosarcoma conditioned media, 125I-labeled MCP-1 receptor binding competition assay, monocyte chemotaxis and activation assays, in vivo subcutaneous injection in Lewis rats\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro functional assays plus in vivo model, multiple orthogonal methods in single study\",\n      \"pmids\": [\"2161898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In spinal cord astrocytes, TNF-α activates JNK via TNF receptor-1, which drives CCL2/MCP-1 upregulation; astrocyte-derived MCP-1 then acts on CCR2-expressing neurons to enhance excitatory synaptic transmission (spontaneous EPSCs, NMDA- and AMPA-induced currents), causing central sensitization and neuropathic pain.\",\n      \"method\": \"Cytokine array, JNK inhibitor pharmacology (SP600125, D-JNKI-1), spinal nerve ligation model, MCP-1 neutralizing antibody injection, patch-clamp recordings in spinal cord slices, immunohistochemistry\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including electrophysiology, in vivo genetic/pharmacological intervention, and cellular imaging\",\n      \"pmids\": [\"19339605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MCP-1 expressed in adipose tissue drives macrophage infiltration into adipose tissue, systemic insulin resistance, and hepatic steatosis in obesity; MCP-1 KO mice fed a high-fat diet show extensive reduction of these phenotypes, and acute expression of a dominant-negative MCP-1 mutant (7ND) ameliorated insulin resistance in obese mice.\",\n      \"method\": \"MCP-1 transgenic mice (aP2 promoter), MCP-1 homozygous KO mice, high-fat diet model, db/db mice, dominant-negative MCP-1 mutant gene therapy\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mouse models (KO and transgenic) with defined metabolic phenotypes replicated across conditions\",\n      \"pmids\": [\"16691291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"MCP-1 KO mice display significantly delayed wound re-epithelialization, reduced angiogenesis (48% reduction in capillary density at day 5), and impaired collagen synthesis, without change in wound macrophage number, indicating MCP-1 regulates wound healing primarily by influencing macrophage effector state rather than recruitment.\",\n      \"method\": \"MCP-1 KO and MIP-1α KO mice, wound re-epithelialization histomorphometry, capillary density counts, hydroxyproline quantification\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular and biochemical phenotypic readouts\",\n      \"pmids\": [\"11485904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Upon MCP-1 stimulation, iPLA2β translocates from cytoplasm to the membrane-enriched pseudopod and regulates both speed and directionality of monocyte chemotaxis, as well as actin polymerization; cPLA2α translocates to the endoplasmic reticulum and regulates speed only. Both enzymes are required for monocyte migration in vivo to the peritoneum.\",\n      \"method\": \"Antisense oligodeoxynucleotide knockdown, intracellular localization imaging, actin polymerization assay, adoptive transfer in vivo monocyte migration assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanistic localization plus in vivo functional validation with multiple orthogonal methods\",\n      \"pmids\": [\"18208975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endothelial MCP-1 signals through monocyte CCR2 to promote firm monocyte adhesion to inflamed endothelium under physiological flow via β2-integrin (but not β1-integrin) activation, with MCP-1 inducing rapid neoepitope 24 expression on β2-integrin α-chains.\",\n      \"method\": \"Flow chamber assay with TNF-α-activated primary human pulmonary artery endothelial cells, anti-MCP-1 mAb neutralization, MCP-1 antisense oligomers, anti-CCR2 mAb, MCP-1 antagonist (9-76 analog), β2/β1-integrin blocking antibodies, mAb24 reporter binding\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological and antibody interventions with specific integrin pathway identification under physiological conditions\",\n      \"pmids\": [\"12388329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IκBζ, an atypical IκB family member and transcriptional coactivator, is directly recruited to the proximal promoter of the CCL2 gene and is required for its transcription-enhancing histone H3K4 trimethylation; IκBζ-deficient macrophages show impaired CCL2 secretion in response to LPS or peptidoglycan, and IκBζ KO mice show impaired CCL2 secretion and monocyte infiltration in experimental peritonitis.\",\n      \"method\": \"IκBζ KO macrophages, chromatin immunoprecipitation (ChIP), ELISA, murine peritonitis model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP (Tier 1) plus in vivo KO model with defined phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"23547114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cocaine induces MCP-1 expression in microglia through translocation of the sigma receptor to lipid raft microdomains, followed by sequential activation of Src, MAPKs, PI3K/Akt, and NF-κB pathways; conditioned medium from cocaine-exposed microglia increases monocyte transmigration via CCR2, an effect absent in CCR2 KO mice.\",\n      \"method\": \"Sigma receptor antagonist pharmacology, lipid raft fractionation, signaling pathway inhibitors, CCR2 KO mice, monocyte transmigration assay, in vivo mouse model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors plus genetic KO validation in vitro and in vivo\",\n      \"pmids\": [\"20354174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Noradrenaline increases MCP-1 expression in astrocytes via β2-adrenergic receptor/cAMP signaling, and astrocyte-derived MCP-1 mediates neuroprotection by reducing NMDA-dependent glutamate release and glutamate-induced Ca2+ entry in neurons, protecting against oxygen-glucose deprivation injury.\",\n      \"method\": \"Primary astrocyte/neuron cultures, MCP-1 promoter-luciferase reporter, β-adrenergic agonists/antagonist pharmacology, cAMP analog, MCP-1 neutralizing antibody, Ca2+ imaging, LDH assay, OGD model, transwell co-culture\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assay, pharmacological receptor identification, neutralizing antibody rescue, multiple functional readouts\",\n      \"pmids\": [\"19129402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MCP-1 deficiency in osteoclast precursors leads to elevated bone mass due to reduced osteoclastogenesis; MCP-1 is required for normal actin ring formation in osteoclasts, and its absence reduces c-Fms and RANK receptor expression and impairs ERK, Akt, Rac1, and Rho activation downstream of M-CSF stimulation.\",\n      \"method\": \"MCP-1 KO mice, micro-CT, serum bone turnover markers (CTX-1, TRACP 5b), in vitro osteoclastogenesis assay, actin ring staining, signaling pathway analysis by western blot\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined skeletal phenotype, in vitro mechanistic dissection of signaling pathway\",\n      \"pmids\": [\"21678414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BMI1, a polycomb protein, represses CCL2/MCP-1 expression by binding to regulatory elements in the CCL2 gene and maintaining H2AK119 ubiquitination; decline in BMI1 during mesenchymal stromal cell (MSC) senescence leads to epigenetic derepression of MCP-1, which then reinforces senescence via CCR2-ROS-p38-MAPK-p53/p21 signaling in autocrine/paracrine fashion.\",\n      \"method\": \"ChIP assay (BMI1 binding to CCL2 regulatory elements, H2AK119Ub), CCR2 knockdown, ROS measurement, signaling inhibitors, MSC expansion/senescence model, in vivo allergic asthma model\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct epigenetic regulation, pathway dissection with KD, in vivo functional consequence\",\n      \"pmids\": [\"26573462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Notch signaling in hepatocytes drives CCL2/MCP-1 transcription via a conserved Notch/RBPJ binding site in the Ccl2 promoter; hepatocyte-specific Ccl2 KO reduces liver monocyte-derived macrophage (MoMF) infiltrate and fibrosis in NASH, while forced hepatocyte MCP-1 expression provokes the opposite phenotype reversible by CCR2 inhibitor treatment.\",\n      \"method\": \"Hepatocyte-specific Ccl2 KO mice, gain-of-function Notch mice, NASH diet model, Ccl2 promoter Notch/RBPJ binding site analysis, CCR2 inhibitor pharmacology, histology, flow cytometry\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — hepatocyte-specific KO plus gain-of-function with defined molecular mechanism (RBPJ binding site) and pharmacological rescue\",\n      \"pmids\": [\"36752206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OxLDL binds MCP-1 via basic amino acids Arg-18 and Lys-19 through oxidized phospholipids (OxPLs); this interaction is blocked by anti-OxPL antibody E06. Lipoprotein(a) [Lp(a)], which carries OxPLs in human plasma, also binds MCP-1 in vivo, and Lp(a)-associated endogenous MCP-1 retains monocyte-recruiting activity.\",\n      \"method\": \"In vitro MCP-1-OxLDL binding assay, Arg18/Lys19 Ala mutant MCP-1, E06 antibody competition, human plasma Lp(a) capture, monocyte migration assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with site-directed mutagenesis and in vivo plasma binding validation\",\n      \"pmids\": [\"23667177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MCP-1 secreted by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts (proliferation, α-SMA upregulation/redistribution, NTPDase2 loss, α1-procollagen upregulation) via receptors distinct from CCR2; bile duct epithelial secretions induce α-SMA in portal fibroblasts in a manner blocked by MCP-1 neutralizing antibody.\",\n      \"method\": \"MCP-1 neutralizing antibody, portal fibroblast functional assays (proliferation, α-SMA, NTPDase2, procollagen), paracrine co-culture system\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, neutralizing antibody plus multiple functional readouts; receptor identity defined only as 'not CCR2'\",\n      \"pmids\": [\"16282363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p53 directly binds a binding site ~2.5 kb upstream of the CCL2/MCP-1 transcriptional start and is required for TNF-α-induced MCP-1 transcription in keratinocytes; loss of p53 function (via HPV E6-mediated degradation, temperature-sensitive p53 mutant, or siRNA) reduces MCP-1 transcription.\",\n      \"method\": \"EMSA, chromatin immunoprecipitation (ChIP), p53 siRNA, temperature-sensitive p53 mutant cells, Li-Fraumeni cells, promoter-luciferase reporter\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — EMSA and ChIP demonstrating direct p53-CCL2 promoter interaction, validated in multiple genetic contexts\",\n      \"pmids\": [\"20406462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Hemin induces MCP-1 mRNA expression in renal proximal tubular cells through two mechanisms: (1) an early HO-dependent, iron-dependent, ROS/NF-κB-mediated pathway (blocked by HO inhibitor ZnPP, iron chelator, N-acetylcysteine, or NF-κB inhibitors TPCK and BAY 11-7082); and (2) a delayed HO-independent pathway at 18 h.\",\n      \"method\": \"HO activity inhibitor (ZnPP), iron chelator, cell-permeant iron, N-acetylcysteine, NF-κB inhibitors, RT-PCR\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological interventions dissecting two distinct pathways in single study\",\n      \"pmids\": [\"12556365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"EBV induces MCP-1 secretion by human monocytes via TLR2; UV-inactivated EBV virions activate NF-κB through TLR2 in HEK293-TLR2 cells (blocked by anti-TLR2 antibody or anti-EBV antibody), and TLR2 siRNA knockdown in primary monocytes significantly reduces EBV-induced MCP-1 release.\",\n      \"method\": \"TLR2-transfected HEK293 cells, NF-κB luciferase reporter, blocking antibodies (anti-TLR2, anti-EBV 72A1), TLR2 siRNA knockdown, ELISA\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay, antibody neutralization, and siRNA knockdown provide convergent evidence for TLR2 as the upstream receptor\",\n      \"pmids\": [\"17522215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PGE2 induces MCP-1 release from mast cells within 2 h via EP1 and EP3 receptor subtypes independently, without degranulation or increased MCP-1 gene expression; immunoelectron microscopy localizes MCP-1 to a non-granule cytoplasmic compartment in mast cells.\",\n      \"method\": \"Primary mast cell cultures, EP receptor subtype agonists, dexamethasone/cyclosporine A inhibition, immunoelectron microscopy, degranulation assay, gene expression analysis\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor subtype pharmacology with ultrastructural localization, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16275896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"HO-1 overexpression in renal proximal tubular cells reduces albumin-stimulated MCP-1 production by inhibiting NF-κB activation at a site distal to ERK activation; albumin-induced MCP-1 induction is critically dependent on intact NF-κB binding sites in the MCP-1 promoter.\",\n      \"method\": \"Stable HO-1 overexpressing NRK-52E cells, NF-κB binding site mutant MCP-1 promoter-reporter, ERK/MEK inhibitor U0126, NF-κB activation assay (EMSA/western), ELISA\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis plus genetic overexpression model with signaling inhibitors\",\n      \"pmids\": [\"16968890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"17β-estradiol inhibits MCP-1 gene expression in keratinocytes through estrogen receptor β (ERβ), which associates in an E2-dependent manner with Sp1 and AP-1 transcription factors and represses their transcriptional activities without blocking their DNA binding; the A/B region and intact activation function 2 of ERβ are required for this inhibitory effect.\",\n      \"method\": \"MCP-1 promoter-luciferase reporter, Sp1/AP-1 transcriptional activity assays, co-immunoprecipitation (ERβ with Sp1/AP-1), ERβ deletion/AF-2 mutation constructs, estrogen receptor antagonist ICI 182780\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — co-IP, promoter reporter, domain mutagenesis providing mechanistic detail, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12787135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ATF4, an ER stress-inducible transcription factor, regulates MCP-1 production in brain and retinal microvascular endothelial cells; ATF4 overexpression increases MCP-1 secretion through NF-κB, p38, and JNK phosphorylation, while ATF4 KO or dominant-negative ATF4 reduces LPS-induced MCP-1 production both in vitro and in vivo.\",\n      \"method\": \"ATF4 KO mice, adenoviral ATF4 overexpression/dominant-negative, intravitreal injection, NF-κB/p38/JNK pharmacological inhibitors, monocyte adhesion and migration assays, ELISA\",\n      \"journal\": \"Journal of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and overexpression plus pharmacological pathway dissection, in vitro and in vivo\",\n      \"pmids\": [\"25914608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"12(S)-HETE, a product of 12/15-lipoxygenase, increases MCP-1 mRNA and protein expression in macrophages via PKC, p38 MAPK, and NADPH oxidase activation; MCP-1 expression is upregulated in 12/15-LO overexpressing macrophages and reduced in 12/15-LO KO macrophages.\",\n      \"method\": \"12/15-LO transgenic and KO mice, macrophage cell line stably overexpressing 12/15-LO, PKC/p38/NADPH oxidase inhibitors, RT-PCR, ELISA\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic gain- and loss-of-function plus pharmacological pathway dissection\",\n      \"pmids\": [\"18296557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Resident muscularis macrophage-derived MCP-1 mediates leukocyte recruitment into the intestinal muscularis during LPS-induced endotoxemia; MCP-1 antibody treatment prevents both leukocyte extravasation and muscle contractile dysfunction (ileus).\",\n      \"method\": \"RT-PCR, immunohistochemistry, organ bath contractility assay, anti-MCP-1 antibody treatment in rats, LPS endotoxemia model\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody neutralization with defined cellular and functional phenotypic readouts in vivo\",\n      \"pmids\": [\"11751168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MCP-1 and TGF-β form a regulatory loop in glomerular injury: MCP-1 stimulates TGF-β production in resident glomerular cells, while TGF-β reduces MCP-1 production; neutralizing either cytokine modulates the other in isolated perfused kidneys.\",\n      \"method\": \"Isolated perfused rat kidney model (anti-thymocyte serum-induced glomerular injury), anti-MCP-1 and anti-TGF-β neutralizing antibodies, recombinant MCP-1 and TGF-β perfusion, TGF-β protein/mRNA measurement\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal neutralization experiments in isolated organ system demonstrate bidirectional regulatory loop\",\n      \"pmids\": [\"12372783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In the aortic ring model of angiogenesis, MCP-1 mediates mural cell recruitment downstream of angiopoietin-1/p38 MAPK signaling; recombinant MCP-1 dose-dependently increases mural cell number, anti-MCP-1 blocking antibody reduces it and abrogates Ang-1's stimulatory effect, and MCP-1 KO or CCR2 KO mouse aortic rings have fewer mural cells than controls.\",\n      \"method\": \"Aortic ring assay, recombinant MCP-1, anti-MCP-1 blocking antibody, MCP-1 KO and CCR2 KO mice, p38 MAPK inhibitor, immunostaining\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody and genetic KO approaches with quantitative mural cell readout in ex vivo angiogenesis model\",\n      \"pmids\": [\"20571857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ischemia-reperfusion injury induces MCP-1 release from cardiomyocytes, which activates MCPIP1 (MCP-1-induced protein-1) and CaSR (Ca2+-sensing receptor) to induce cardiomyocyte apoptosis through ER stress (not autophagy); CaSR acts as an upstream effector of MCPIP1 in this pathway.\",\n      \"method\": \"HL-1 cardiomyocyte cell line and primary neonatal cardiomyocytes, CCR2 inhibitor (RS-102895), CaSR inhibitor (NPS-2143) and activator (evocalcet), Hoechst staining, flow cytometry apoptosis assay, western blot, ELISA\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with specific receptor inhibitors/activators establishing CaSR-MCPIP1-ER stress cascade, single lab\",\n      \"pmids\": [\"31774703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-374a directly targets and negatively regulates MCP-1 (CCL2) mRNA expression in renal tubular epithelial cells; miR-374a mimic reduces MCP-1 expression and monocyte migration, while miR-374a inhibition has the opposite effect, and MCP-1 overexpression reverses the inhibitory effects of miR-374a mimic.\",\n      \"method\": \"miR-374a mimic/inhibitor transfection in HK2 cells, bioinformatics target prediction, MCP-1 overexpression rescue, U937 cell migration assay, RT-PCR, ELISA\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — miRNA target validation with rescue experiment but without 3'UTR luciferase assay; single lab\",\n      \"pmids\": [\"30147653\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL2/MCP-1 is a secreted CC chemokine that acts through its G-protein-coupled receptor CCR2 to drive monocyte/macrophage chemotaxis and activation; it is transcriptionally regulated by NF-κB, p53, IκBζ, ATF4, and Notch/RBPJ signaling, epigenetically repressed by BMI1-mediated H2AK119 ubiquitination at the CCL2 locus, and post-transcriptionally suppressed by miR-374a; downstream of CCR2, it activates iPLA2β-dependent actin remodeling and directional migration, β2-integrin-mediated firm adhesion, and PI3K/Akt, MAPK, and NF-κB pathways to drive inflammatory cell recruitment, osteoclast actin ring formation, astrocytic central sensitization, and cardiomyocyte apoptosis via MCPIP1/CaSR-ER stress.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"CCL2/MCP-1 was cloned and sequenced from a glioma cell line cDNA library; the precursor protein consists of a 23-residue signal peptide and a 76-residue mature protein, establishing it as a member of the inducible cytokine family with sequence similarity to mouse JE, RANTES, MIP, and TCA-3.\",\n      \"method\": \"cDNA cloning, nucleotide sequencing, amino acid sequence analysis\",\n      \"journal\": \"Biochemical and biophysical research communications / FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary sequence determination by cloning and sequencing, replicated across two independent labs (PMID:2923622 and PMID:2465924)\",\n      \"pmids\": [\"2923622\", \"2465924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CCL2/MCP-1 mRNA is induced in human peripheral blood mononuclear leukocytes by PHA, LPS, and IL-1, but not by IL-2, TNF, or IFN-γ, defining the stimulus-specific transcriptional regulation of the gene.\",\n      \"method\": \"Northern blot analysis, mRNA induction assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA induction experiments in primary human cells, foundational characterization paper\",\n      \"pmids\": [\"2465924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Purified CCL2/MCAF specifically binds to receptors on human PBMC that are distinct from those used by IL-8, stimulates superoxide anion release and N-acetyl-β-D-glucosaminidase secretion in human monocytes, augments monocyte cytostatic activity against tumor cells, and induces in vivo local monocyte infiltration in rat ears, establishing CCL2 as both a monocyte chemoattractant and activator.\",\n      \"method\": \"Protein purification, competitive receptor-binding assays with 125I-labeled MCAF, in vitro functional assays, in vivo subcutaneous injection\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein with multiple orthogonal functional assays and in vivo validation\",\n      \"pmids\": [\"2161898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Transcription of the human CCL2 gene is controlled by two critical cis-elements: a remote NF-κB binding site (at bp −2612 to −2603) required for IL-1β-, TNF-α-, and PMA-induced enhancer activity, and a proximal GC box (bp −64 to −59) bound by Sp1 that maintains basal transcriptional activity.\",\n      \"method\": \"5′-flanking genomic DNA sequencing, promoter-reporter assays, site-directed mutagenesis, Sp1 overexpression\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of specific promoter elements combined with reporter assays and transcription factor overexpression\",\n      \"pmids\": [\"8051410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL2/MCP-1 knockout mice show significantly delayed wound re-epithelialization, reduced angiogenesis, and impaired collagen synthesis compared to wild-type, without a change in macrophage numbers in wounds, indicating CCL2 regulates the effector state of macrophages and other wound-repair cells rather than simply mediating monocyte recruitment into wounds.\",\n      \"method\": \"MCP-1 knockout mouse model, wound healing assay, histology, hydroxyproline quantification, capillary density measurement\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"11485904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Matrix metalloproteinases MMP-1 and MMP-3 cleave CCL2 between residues 4 and 5; the resulting truncated CCL2 product binds CCR2 but lacks chemoattractant activity and acts as a CCR2 antagonist, reducing inflammatory edema in vivo by >66%, revealing a proteolytic mechanism by which MMPs terminate CCL2-driven chemotaxis.\",\n      \"method\": \"Recombinant MMP cleavage assays, receptor-binding assays, transwell migration assays, in vivo carrageenan inflammation model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted cleavage with mutagenesis-equivalent synthetic analogs, functional receptor antagonism, and in vivo validation\",\n      \"pmids\": [\"12149192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endothelial-derived CCL2 signals through monocyte CCR2 to promote firm monocyte adhesion to inflamed endothelium under physiological flow via the β2-integrin (but not β1-integrin) pathway; MCP-1 stimulation causes rapid β2-integrin neoepitope 24 expression on monocytes, establishing a mechanistic link between endothelial CCL2 and integrin-mediated monocyte adhesion.\",\n      \"method\": \"Flow chamber assay, anti-MCP-1 neutralizing antibody, antisense oligomers, CCR2 blockade, anti-integrin antibodies, reporter mAb24 binding\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological and antibody-based blockade strategies under physiological flow conditions with integrin pathway dissection\",\n      \"pmids\": [\"12388329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL2 secreted by bile duct epithelia acts in a paracrine manner on portal fibroblasts to induce their proliferation, α-smooth muscle actin redistribution (myofibroblastic transdifferentiation), loss of NTPDase2, and upregulation of α1-procollagen; these effects are mediated by a receptor on portal fibroblasts distinct from CCR2.\",\n      \"method\": \"MCP-1 blocking antibody, paracrine co-culture assays, proliferation assays, immunofluorescence for α-SMA, NTPDase2 assay, procollagen measurement\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade and paracrine culture system with multiple readouts; single lab\",\n      \"pmids\": [\"16282363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MCP-1 transgenic overexpression in adipose tissue causes macrophage infiltration, insulin resistance, and hepatic steatosis, while MCP-1 knockout reduces these phenotypes in diet-induced obese mice, and acute expression of a dominant-negative MCP-1 mutant ameliorates insulin resistance, establishing a causal role of CCL2 in obesity-induced metabolic inflammation.\",\n      \"method\": \"Transgenic mouse overexpression (aP2-MCP-1), MCP-1 homozygous knockout mice, dominant-negative mutant gene delivery, metabolic phenotyping\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — triangulated with gain-of-function transgenic, loss-of-function knockout, and acute dominant-negative rescue; multiple labs cited\",\n      \"pmids\": [\"16691291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"EBV virions induce MCP-1 secretion from human monocytes through TLR2 recognition, activating NF-κB; siRNA-mediated TLR2 knockdown significantly reduces CCL2 release, identifying TLR2 as the pattern recognition receptor upstream of CCL2 induction during EBV infection.\",\n      \"method\": \"TLR2-expressing HEK293 transfection, NF-κB-luciferase reporter assay, blocking anti-TLR2 antibodies, siRNA knockdown, ELISA\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA and antibody blockade in primary monocytes with reporter assays; single lab\",\n      \"pmids\": [\"17522215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"12(S)-HETE (a product of 12/15-lipoxygenase) increases CCL2 mRNA and protein expression in macrophages via sequential activation of PKC, p38 MAPK, and NADPH oxidase; 12/15-LO knockout mice have reduced macrophage MCP-1 expression, and transgenic overexpression of 12/15-LO increases it, defining a 12/15-LO→PKC/p38/NADPH oxidase→CCL2 regulatory axis.\",\n      \"method\": \"12(S)-HETE treatment, PKC/p38/NADPH oxidase pharmacological inhibitors, 12/15-LO transgenic and knockout mouse peritoneal macrophages, stable 12/15-LO overexpressing cell line\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological inhibitors combined with transgenic and knockout mouse models in parallel\",\n      \"pmids\": [\"18296557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Upon MCP-1 stimulation, iPLA2β translocates to the membrane-enriched pseudopod while cPLA2α is recruited to the endoplasmic reticulum; iPLA2β regulates monocyte directionality and actin polymerization in addition to speed, whereas cPLA2α affects speed alone; antisense knockdown of either enzyme impairs monocyte migration to the peritoneum in vivo.\",\n      \"method\": \"Antisense oligodeoxynucleotides, subcellular localization imaging, transwell chemotaxis assays, actin polymerization assay, adoptive transfer in vivo migration assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — intracellular localization linked to specific functional outcomes (directionality vs. speed) with in vivo validation\",\n      \"pmids\": [\"18208975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TNF-α activates JNK in spinal astrocytes via TNF receptor-1, leading to CCL2/MCP-1 induction; JNK inhibitors block this upregulation dose-dependently. Spinal MCP-1 subsequently activates ERK in dorsal horn neurons, enhances spontaneous EPSCs, and potentiates NMDA- and AMPA-induced currents, contributing to central sensitization and neuropathic pain.\",\n      \"method\": \"JNK inhibitors (SP600125, D-JNKI-1), cytokine array, spinal nerve ligation model, MCP-1 neutralizing antibody intrathecal injection, patch-clamp recordings in spinal cord slices\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological tools, electrophysiology, and in vivo model; mechanistic pathway from kinase to synaptic transmission defined\",\n      \"pmids\": [\"19339605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Noradrenaline increases CCL2 expression in astrocytes via β2-adrenergic receptor–cAMP signaling activating the MCP-1 promoter; astrocyte-released MCP-1 reduces NMDA-dependent glutamate release and glutamate-mediated Ca2+ entry in neurons, protecting them from OGD-induced damage; neutralizing antibody to MCP-1 blocks the neuroprotective effect of conditioned medium from NA-treated astrocytes.\",\n      \"method\": \"β-adrenergic agonists/antagonists, cAMP analog, MCP-1 promoter–luciferase assay, MCP-1 neutralizing antibody, glutamate release assay, Ca2+ imaging, LDH assay, OGD model, transwell co-culture\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor pharmacology, promoter assay, and neutralizing antibody with multiple neuronal endpoint assays\",\n      \"pmids\": [\"19129402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cocaine induces CCL2 expression in microglia through translocation of the sigma receptor to lipid raft microdomains, followed by sequential activation of Src, MAPKs, PI3K/Akt, and NF-κB; conditioned medium from cocaine-exposed microglia increases monocyte transmigration via CCR2, and this effect is absent in CCR2 knockout mice or with sigma receptor antagonist pretreatment.\",\n      \"method\": \"Sigma receptor antagonist, lipid raft fractionation, kinase inhibitors, CCR2 knockout mice, monocyte transmigration assay, in vivo cocaine exposure\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissection with pharmacological inhibitors and genetic knockout, in vitro and in vivo convergent evidence\",\n      \"pmids\": [\"20354174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Thiamine deficiency selectively induces neuronal CCL2 expression prior to microglia activation; MCP-1 from thiamine-deficient neurons activates microglia to produce cytotoxic cytokines; MCP-1 neutralizing antibody inhibits microglia activation and neuronal death; CCL2 knockout mice are resistant to thiamine deficiency-induced neurodegeneration in the thalamus.\",\n      \"method\": \"Thiamine deficiency model, neuron/microglia co-culture, MCP-1 neutralizing antibody, CCL2 knockout mice, antioxidant treatment\",\n      \"journal\": \"Brain pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus neutralizing antibody in both in vitro and in vivo settings\",\n      \"pmids\": [\"21029241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL2 produced by tumor and stroma recruits Gr1+ inflammatory monocytes expressing CCR2 to pulmonary metastases; these inflammatory monocytes promote tumor cell extravasation via monocyte-derived VEGF; inhibition of CCL2-CCR2 signaling blocks monocyte recruitment and inhibits metastasis in vivo, defining a CCL2→CCR2→VEGF→extravasation mechanistic axis in breast cancer metastasis.\",\n      \"method\": \"CCL2-knockout mice, CCL2 antibody blockade, bone marrow chimeras, monocyte depletion, VEGF measurement, in vivo metastasis model\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and antibody-based loss-of-function approaches with mechanistic VEGF link; high-impact publication\",\n      \"pmids\": [\"21654748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Reactive nitrogen species within the tumor microenvironment nitrate CCL2, and this nitrated form fails to recruit T cells into the tumor core, trapping them in the surrounding stroma; drugs that inhibit CCL2 nitration restore CTL invasion, revealing RNS-mediated post-translational modification of CCL2 as a tumor immune evasion mechanism.\",\n      \"method\": \"RNS detection in tumor microenvironment, chemokine nitration biochemistry, T cell trafficking assays, pharmacological inhibition of CCL2 modification in mouse and human tumors\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — novel post-translational modification (nitration) with functional consequence on leukocyte trafficking, validated in mouse and human tumors\",\n      \"pmids\": [\"21930770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL2 deficiency in ApcMin/+ mice reduces polyp number (especially large polyps) and decreases F4/80+ macrophages in polyp and intestinal tissue, shifts cytokine balance (reduces IL-1β, IL-6, increases SOCS1), increases cytotoxic T lymphocytes and decreases regulatory T cells, establishing CCL2 as a mediator of tumor-associated macrophage recruitment and immune regulation in intestinal tumorigenesis.\",\n      \"method\": \"MCP-1 knockout in ApcMin/+ genetic background, histology, immunohistochemistry, cytokine mRNA quantification\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic knockout with multiple immune and tumor endpoints; single lab\",\n      \"pmids\": [\"23019193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MCP-1 deficiency in mice leads to elevated bone mass due to reduced osteoclast number and activity; MCP-1-null osteoclast precursors show reduced c-Fms and RANK receptor levels, impaired actin ring formation, and reduced activation of ERK, Akt, Rac1, and Rho upon M-CSF stimulation, placing CCL2 upstream of M-CSF signaling and cytoskeletal organization in osteoclastogenesis.\",\n      \"method\": \"MCP-1 knockout mice, bone densitometry, serum CTX-1 and TRACP 5b, in vitro osteoclastogenesis, actin ring staining, Western blot for signaling molecules\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with mechanistic signaling readouts; single lab\",\n      \"pmids\": [\"21678414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IκBζ, an atypical IκB family member and NF-κB transcriptional coactivator, directly binds the proximal promoter of the Ccl2 gene (shown by ChIP) and is required for LPS- and peptidoglycan-induced CCL2 secretion in macrophages; IκBζ-deficient mice show impaired CCL2 secretion and monocyte infiltration in peritonitis; IκBζ binding enables transcription-enhancing H3K4 trimethylation at the Ccl2 promoter.\",\n      \"method\": \"IκBζ-knockout macrophages, chromatin immunoprecipitation (ChIP), histone methylation assay, peritonitis model, ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP demonstrates direct promoter occupancy, genetic knockout, epigenetic mark identified, in vivo validation\",\n      \"pmids\": [\"23547114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"OxLDL binds CCL2 through oxidized phospholipids, and basic residues Arg-18 and Lys-19 in CCL2 are required for this interaction (shown by Arg18Ala/Lys19Ala mutant that fails to bind OxLDL); lipoprotein(a) in human plasma also binds CCL2 via oxidized phospholipids, and Lp(a)-associated endogenous MCP-1 retains monocyte-recruiting activity.\",\n      \"method\": \"OxLDL binding assay, site-directed mutagenesis (R18A/K19A), monoclonal antibody E06 blocking, human plasma Lp(a) capture, monocyte migration assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis identifies specific binding residues, confirmed in human plasma with functional monocyte migration readout\",\n      \"pmids\": [\"23667177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL2 produced by tumor-derived macrophages/microglia recruits both CCR4+ regulatory T cells and CCR2+Ly-6C+ monocytic MDSCs into gliomas; glioma-derived CCL20 and osteoprotegerin induce CCL2 production from macrophages/microglia; in mixed bone marrow chimera assays, CCR4-deficient Tregs and CCR2-deficient monocytic MDSCs fail to accumulate in gliomas.\",\n      \"method\": \"CCL2-deficient mice, mixed bone marrow chimeras, CCR4/CCR2 knockout cells, small-molecule CCR4 antagonist, survival analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout and chimera experiments combined with pharmacological CCR4 blockade; mechanistic induction pathway identified\",\n      \"pmids\": [\"27530322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL2 promotes macrophage M2 polarization: CCL2 enhances LPS-induced IL-10 production, while CCL2 blockade increases M1 markers and reduces M2 markers in human macrophages; Ccr2-deficient murine macrophages display M1-skewed polarization with higher TNF-α and IL-6 in response to LPS; activin A controls differential CCL2/CCR2 expression, inhibiting CCL2 acquisition by M-CSF-polarized macrophages.\",\n      \"method\": \"CCL2 blocking antibody, Ccr2-knockout bone marrow-derived macrophages, gene expression profiling, cytokine ELISA, activin A treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antibody blockade plus genetic knockout with transcriptomic profiling; replicated in human and murine systems\",\n      \"pmids\": [\"24639350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ATF4, an ER stress-inducible transcription factor, is a key regulator of CCL2 production in microvascular endothelial cells; ATF4 overexpression increases CCL2 secretion and promotes monocyte adhesion, while ATF4-deficient endothelial cells and ATF4 heterozygous knockout retinas show markedly attenuated LPS-induced CCL2; ATF4 acts upstream of NF-κB, p38, and JNK phosphorylation to drive CCL2 expression.\",\n      \"method\": \"ATF4 knockout mice, adenoviral ATF4 overexpression/dominant-negative, LPS stimulation, pharmacological inhibition of NF-κB/p38/JNK, monocyte adhesion assay, intravitreal injection\",\n      \"journal\": \"Journal of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and adenoviral gain/loss-of-function with signaling pathway inhibitors; single lab\",\n      \"pmids\": [\"25914608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"During mesenchymal stromal cell senescence, MCP-1 is secreted as a dominant SASP component and reinforces senescence via CCR2-activated ROS-p38-MAPK-p53/p21 cascade in autocrine/paracrine fashion; activated p53 further increases MCP-1 secretion, forming a feed-forward loop; BMI1 epigenetically represses CCL2 expression by binding its regulatory elements and maintaining H2AK119Ub; BMI1 decline during senescence leads to loss of this mark and CCL2 derepression.\",\n      \"method\": \"CCR2 knockdown, p38/MAPK/p53 inhibitors, ChIP for BMI1 and H2AK119Ub, ROS measurement, SASP profiling by ELISA\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP identifies specific epigenetic regulator and histone mark, combined with siRNA knockdown and pharmacological pathway dissection\",\n      \"pmids\": [\"26573462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CCL2/CCR2 signaling shapes macrophage behavior beyond chemotaxis, including promoting survival of CD11b+ monocytes via upregulation of cFLIPL, Bcl-2, and Bcl-XL and inhibition of caspase-8 cleavage; CCL2 induces autophagy hyperactivation and M2-type (CD206+) macrophage polarization; blockade of autophagic degradation reverses CCL2-induced M2 polarization.\",\n      \"method\": \"CCL2 stimulation of primary human CD11b+ cells, Western blot for apoptotic proteins, caspase-8 activity assays, flow cytometry for CD206, autophagy inhibitor treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts in primary human cells; single lab\",\n      \"pmids\": [\"19833726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hepatocyte-specific CCL2 expression is driven by Notch signaling through an evolutionarily conserved RBPjκ binding site in the Ccl2 promoter; hepatocyte-specific Ccl2 knockout reduces liver monocyte-derived macrophage infiltration and fibrosis in NASH, while forced hepatocyte MCP-1 expression produces the opposite phenotype; the effect is rescued by CCR2 inhibitor treatment.\",\n      \"method\": \"Hepatocyte-specific Ccl2 knockout mice, Notch gain-of-function mice, Ccl2 promoter analysis for RBPjκ binding site, CCR2 inhibitor treatment, liver histology and fibrosis quantification\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — tissue-specific knockout plus gain-of-function with promoter mechanistic analysis; pharmacological rescue confirms pathway\",\n      \"pmids\": [\"36752206\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL2/MCP-1 is a secreted CC chemokine (76-residue mature protein with 23-residue signal peptide, gene regulated by NF-κB and Sp1 at the promoter and additionally by transcriptional coactivators IκBζ, ATF4, p53, and epigenetic repressor BMI1) that acts as a potent, specific monocyte/macrophage chemoattractant and activator by binding its primary receptor CCR2 (a Gαi-coupled GPCR), triggering Ca2+ flux, chemotaxis via iPLA2β-regulated actin polarization, β2-integrin-mediated firm adhesion to endothelium, and downstream PI3K/Akt, Src/MAPK, and NF-κB signaling; beyond chemotaxis, CCL2-CCR2 signaling promotes M2 macrophage polarization via caspase-8 inhibition and autophagy, drives myofibroblast transdifferentiation, regulates osteoclast actin ring formation and M-CSF signaling, mediates cardiomyocyte apoptosis through MCPIP1 and CaSR, induces excitatory synaptic transmission in spinal neurons contributing to neuropathic pain, and can be post-translationally inactivated by MMP cleavage (between residues 4–5, generating a CCR2 antagonist) or by RNS-mediated nitration that abolishes leukocyte recruitment.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL2/MCP-1 is a secreted CC chemokine that functions as the principal monocyte/macrophage chemoattractant and activator, with broad roles in inflammatory cell recruitment, tissue remodeling, metabolic homeostasis, and neuroprotection/nociception. The mature 76-amino-acid protein signals primarily through its receptor CCR2 to activate β2-integrin-mediated firm adhesion, iPLA2β-dependent actin remodeling and directional migration, and downstream ERK, Akt, Rac1, and NF-κB pathways that drive monocyte extravasation, osteoclastogenesis, wound angiogenesis, and mural cell recruitment [PMID:2161898, PMID:12388329, PMID:18208975, PMID:21678414, PMID:20571857]. CCL2 transcription is positively regulated by NF-κB, p53, IκBζ-dependent H3K4 trimethylation, ATF4, and Notch/RBPJ, and epigenetically repressed by BMI1-mediated H2AK119 ubiquitination; post-transcriptionally, miR-374a suppresses CCL2 mRNA levels [PMID:23547114, PMID:20406462, PMID:36752206, PMID:26573462, PMID:30147653]. In vivo, CCL2 deficiency impairs adipose tissue macrophage infiltration and protects against obesity-driven insulin resistance and hepatic steatosis, while in the CNS astrocyte-derived CCL2 enhances excitatory neurotransmission to promote neuropathic pain and modulates neuroprotection by attenuating NMDA-dependent glutamate toxicity [PMID:16691291, PMID:19339605, PMID:19129402].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Cloning CCL2 established it as a CC chemokine family member with a 23-aa signal peptide and 76-aa mature secreted form, resolving its molecular identity.\",\n      \"evidence\": \"cDNA cloning and sequencing from human PBMC mRNA\",\n      \"pmids\": [\"2923622\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor identified\", \"No functional assay performed in this study\", \"Post-translational modifications not characterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that purified MCP-1 binds specific monocyte receptors (distinct from IL-8 receptors), activates superoxide production and enzyme release, and recruits monocytes in vivo established CCL2 as both a chemoattractant and a monocyte activator.\",\n      \"evidence\": \"125I-MCP-1 receptor binding competition, monocyte functional assays, subcutaneous injection in Lewis rats\",\n      \"pmids\": [\"2161898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor molecular identity unknown at this point\", \"Downstream intracellular signaling pathways unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"MCP-1 KO mice revealed that CCL2 regulates wound re-epithelialization, angiogenesis, and collagen synthesis by modulating macrophage effector function rather than simply recruitment, distinguishing its role from mere chemotaxis.\",\n      \"evidence\": \"MCP-1 KO mice with wound histomorphometry, capillary density, and hydroxyproline quantification\",\n      \"pmids\": [\"11485904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific macrophage effector programs controlled by CCL2 not defined\", \"Redundancy with other chemokines not fully addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Flow chamber experiments showed that endothelial CCL2 activates β2-integrin on monocytes through CCR2 to mediate firm adhesion under physiological shear, identifying the specific adhesion mechanism for CCL2-driven monocyte arrest.\",\n      \"evidence\": \"Flow chamber with TNF-α-activated endothelial cells, anti-MCP-1/CCR2/integrin antibodies, MCP-1 antagonist, mAb24 neoepitope reporter\",\n      \"pmids\": [\"12388329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between CCR2 and β2-integrin activation not mapped\", \"Applicability to all vascular beds not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Multiple studies revealed the transcriptional control logic of CCL2: NF-κB binding sites in the MCP-1 promoter are essential for induction by albumin and hemin, while estrogen receptor β represses CCL2 transcription by tethering to Sp1/AP-1 without blocking DNA binding, and MCP-1/TGF-β form a reciprocal regulatory loop in glomerular injury.\",\n      \"evidence\": \"Promoter-luciferase reporters with NF-κB site mutations, ERβ co-IP with Sp1/AP-1, ERβ domain mutagenesis, isolated perfused kidney with reciprocal neutralizing antibodies, pharmacological NF-κB inhibitors\",\n      \"pmids\": [\"12556365\", \"12787135\", \"12372783\", \"16968890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation not yet addressed\", \"Relative contribution of NF-κB, Sp1, and AP-1 in different cell types unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Transgenic and KO mouse models demonstrated that adipose tissue-derived MCP-1 drives macrophage infiltration, insulin resistance, and hepatic steatosis in obesity, establishing CCL2 as a systemic metabolic inflammatory mediator.\",\n      \"evidence\": \"aP2-MCP-1 transgenic, MCP-1 KO mice on high-fat diet, dominant-negative MCP-1 gene therapy in db/db mice\",\n      \"pmids\": [\"16691291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR2 is the sole receptor mediating metabolic effects not formally tested\", \"Contribution of non-macrophage targets unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Subcellular imaging revealed that MCP-1-stimulated monocyte chemotaxis requires iPLA2β translocation to the pseudopod for directional sensing and cPLA2α translocation to the ER for speed, dissecting the lipase-dependent cytoskeletal remodeling machinery downstream of CCR2.\",\n      \"evidence\": \"Antisense knockdown of PLA2 isoforms, intracellular localization imaging, actin polymerization assay, in vivo adoptive transfer\",\n      \"pmids\": [\"18208975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid second messengers generated by each PLA2 isoform not identified\", \"How CCR2 selectively recruits each PLA2 isoform unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CNS studies showed CCL2 plays dual neuronal roles: astrocyte-derived MCP-1 enhances excitatory synaptic transmission via neuronal CCR2 to produce neuropathic pain (JNK-dependent), while noradrenaline-induced astrocytic MCP-1 is neuroprotective by reducing NMDA-dependent glutamate toxicity, revealing context-dependent neuronal effects.\",\n      \"evidence\": \"Spinal nerve ligation, patch-clamp in spinal cord slices, JNK inhibitors, MCP-1 neutralizing antibody, β2-adrenergic pharmacology, OGD model, Ca2+ imaging\",\n      \"pmids\": [\"19339605\", \"19129402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for opposing neuronal outcomes not resolved\", \"Whether distinct CCR2 signaling complexes mediate pain vs. protection unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"p53 was shown to directly bind the CCL2 promoter ~2.5 kb upstream and is required for TNF-α-induced MCP-1 transcription, while cocaine-induced MCP-1 in microglia proceeds through sigma receptor/lipid raft/Src/MAPK/PI3K/NF-κB signaling to CCR2-dependent monocyte transmigration, broadening the upstream regulatory landscape.\",\n      \"evidence\": \"ChIP and EMSA for p53-CCL2 promoter binding, p53 siRNA/mutant/Li-Fraumeni cells; sigma receptor antagonist, lipid raft fractionation, CCR2 KO mice\",\n      \"pmids\": [\"20406462\", \"20354174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53 cooperates with NF-κB at the CCL2 promoter not tested\", \"Sigma receptor mechanism in non-microglial cells unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"MCP-1 KO mice exhibited elevated bone mass due to impaired osteoclastogenesis: CCL2 is required for actin ring formation and for maintaining c-Fms/RANK expression and ERK/Akt/Rac1/Rho signaling in osteoclast precursors, establishing a bone-homeostatic role.\",\n      \"evidence\": \"MCP-1 KO mice, micro-CT, osteoclastogenesis assay, actin ring staining, western blot signaling analysis\",\n      \"pmids\": [\"21678414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Autocrine vs. paracrine source of CCL2 in bone microenvironment not distinguished\", \"Whether CCR2 is the relevant receptor for osteoclast effects not formally shown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ChIP studies established that IκBζ is directly recruited to the CCL2 promoter where it promotes H3K4 trimethylation for transcriptional activation, and that OxLDL binds MCP-1 through Arg-18/Lys-19 via oxidized phospholipids, with Lp(a)-bound MCP-1 retaining monocyte-recruiting activity in plasma.\",\n      \"evidence\": \"IκBζ KO macrophages, ChIP for IκBζ and H3K4me3, peritonitis model; Arg18/Lys19 Ala mutagenesis, E06 antibody competition, Lp(a) capture from human plasma\",\n      \"pmids\": [\"23547114\", \"23667177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Lp(a)-MCP-1 complexes alter tissue-specific chemokine gradients in vivo unknown\", \"Mechanism by which IκBζ recruits H3K4 methyltransferase not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"BMI1 was shown to repress CCL2 by maintaining H2AK119 ubiquitination at the CCL2 locus; age-related BMI1 decline derepresses CCL2, which then drives mesenchymal stromal cell senescence through an autocrine CCR2-ROS-p38-p53/p21 loop, linking epigenetic control of CCL2 to cellular aging.\",\n      \"evidence\": \"ChIP for BMI1 and H2AK119Ub at CCL2, CCR2 knockdown, ROS measurement, MSC senescence model, in vivo asthma model\",\n      \"pmids\": [\"26573462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other polycomb targets contribute to the senescence phenotype not separated\", \"Generalizability beyond MSCs not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"MCP-1 released during ischemia-reperfusion activates a MCPIP1/CaSR/ER-stress apoptotic cascade in cardiomyocytes, defining a non-chemotactic, pro-apoptotic signaling output distinct from its canonical migratory function.\",\n      \"evidence\": \"HL-1 and neonatal cardiomyocytes, CCR2 inhibitor RS-102895, CaSR inhibitor/activator, flow cytometry apoptosis, western blot\",\n      \"pmids\": [\"31774703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo cardiac phenotype of this specific pathway not validated\", \"Whether MCPIP1 induction is transcriptional or post-transcriptional not determined\", \"Single-lab finding with pharmacological inhibitors only\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Hepatocyte-specific Ccl2 KO and gain-of-function experiments demonstrated that Notch/RBPJ directly transactivates the Ccl2 promoter in hepatocytes, and that hepatocyte-derived CCL2 drives monocyte-derived macrophage infiltration and fibrosis in NASH, reversible by CCR2 inhibition.\",\n      \"evidence\": \"Hepatocyte-specific Ccl2 KO, gain-of-function Notch mice, NASH diet, Ccl2 promoter RBPJ site analysis, CCR2 inhibitor, flow cytometry\",\n      \"pmids\": [\"36752206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other Notch target genes contribute to the fibrotic phenotype in parallel\", \"Therapeutic window for CCR2 inhibition in established NASH not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CCR2 activation by CCL2, how distinct downstream signaling modes (chemotaxis vs. apoptosis vs. synaptic modulation) are specified in different cell types, and whether Lp(a)-bound CCL2 pools contribute to cardiovascular disease pathogenesis in humans.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of CCL2-CCR2 signaling complex available in the timeline\", \"Cell-type-specific signaling branch points downstream of CCR2 not systematically mapped\", \"In vivo significance of Lp(a)-MCP-1 interaction for atherosclerosis not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 2, 6, 10, 25, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 3, 7, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 3, 6, 7, 8, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 8, 10, 11, 26]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [6, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR2\",\n      \"NFKBIZ\",\n      \"TP53\",\n      \"BMI1\",\n      \"PLA2G6\",\n      \"RBPJ\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CCL2 (MCP-1) is a secreted CC chemokine that functions as a principal monocyte/macrophage chemoattractant and activator, orchestrating innate immune cell recruitment in inflammation, tissue repair, metabolic disease, neurodegeneration, and tumor progression. The mature 76-residue protein signals primarily through the Gαi-coupled receptor CCR2 to trigger β2-integrin-dependent firm adhesion to endothelium, iPLA2β-regulated actin polarization and directional migration, and downstream PI3K/Akt, Src/MAPK, and NF-κB cascades; beyond chemotaxis, CCL2–CCR2 signaling promotes M2 macrophage polarization via caspase-8 inhibition and autophagy, drives myofibroblast transdifferentiation, modulates osteoclastogenesis, and enhances excitatory synaptic transmission in spinal neurons [PMID:2161898, PMID:12388329, PMID:18208975, PMID:19833726, PMID:19339605, PMID:21678414]. Transcription is controlled by an NF-κB distal enhancer and a proximal Sp1 site, with additional regulation by IκBζ-dependent H3K4 trimethylation, ATF4, BMI1-mediated H2AK119Ub repression, and Notch/RBPJκ in hepatocytes [PMID:8051410, PMID:23547114, PMID:26573462, PMID:36752206]. CCL2 activity is terminated post-translationally by MMP-1/MMP-3 cleavage between residues 4–5, generating a CCR2 antagonist, or by reactive nitrogen species–mediated nitration that abolishes leukocyte recruitment [PMID:12149192, PMID:21930770].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Molecular cloning of CCL2 from two independent laboratories established its identity as a 99-residue precursor (23-aa signal peptide + 76-aa mature protein) belonging to the CC chemokine family, providing the sequence foundation for all subsequent structure–function work.\",\n      \"evidence\": \"cDNA cloning and sequencing from glioma cell line and stimulated PBMCs\",\n      \"pmids\": [\"2923622\", \"2465924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure not yet determined at this stage\", \"Receptor identity unknown\", \"Post-translational modifications uncharacterized\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Purified CCL2 was shown to bind a specific receptor on monocytes distinct from IL-8 receptors and to activate superoxide release, lysosomal enzyme secretion, tumoricidal activity, and in vivo monocyte infiltration, establishing it as both a chemoattractant and a monocyte activator.\",\n      \"evidence\": \"125I-labeled MCAF competitive binding, functional assays on purified human monocytes, in vivo rat ear injection\",\n      \"pmids\": [\"2161898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor molecular identity not yet cloned\", \"Intracellular signaling cascade undefined\", \"Redundancy with other CC chemokines not addressed\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Promoter dissection resolved how CCL2 transcription is controlled, identifying a distal NF-κB site required for cytokine-induced expression and a proximal Sp1 GC-box for basal activity, explaining how diverse inflammatory stimuli converge on CCL2 induction.\",\n      \"evidence\": \"5′-flanking sequence analysis, promoter-reporter mutagenesis, Sp1 overexpression\",\n      \"pmids\": [\"8051410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin-level regulation and epigenetic marks not addressed\", \"Cell-type-specific promoter usage not explored\", \"Role of enhancer elements beyond the distal NF-κB site unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"CCL2 knockout mice revealed an unexpected role beyond monocyte recruitment: impaired wound re-epithelialization, angiogenesis, and collagen synthesis without altered macrophage numbers, demonstrating that CCL2 regulates macrophage effector function in tissue repair.\",\n      \"evidence\": \"MCP-1 knockout mice, wound healing assay, histology, hydroxyproline and capillary density quantification\",\n      \"pmids\": [\"11485904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effector signals in wound macrophages not identified\", \"Whether CCR2-independent receptors contribute not tested\", \"Compensatory chemokine upregulation not assessed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Two advances defined how CCL2 signaling is executed and terminated: endothelial CCL2 was shown to trigger β2-integrin activation and firm monocyte adhesion under flow via CCR2, while MMP-1/MMP-3 cleavage between residues 4–5 was found to generate a truncated CCR2 antagonist that blocks chemotaxis and reduces inflammation in vivo.\",\n      \"evidence\": \"Flow chamber with anti-integrin/anti-CCR2 blocking antibodies; recombinant MMP cleavage with receptor binding and in vivo carrageenan model\",\n      \"pmids\": [\"12388329\", \"12149192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of MMP cleavage site selectivity not resolved\", \"Kinetics of MMP-mediated inactivation in tissue contexts unknown\", \"Whether other proteases generate similar antagonistic fragments not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Gain-of-function (transgenic), loss-of-function (knockout), and dominant-negative approaches in mice causally linked CCL2 to adipose tissue macrophage infiltration, insulin resistance, and hepatic steatosis, establishing CCL2 as a key mediator of obesity-associated metabolic inflammation.\",\n      \"evidence\": \"aP2-MCP-1 transgenic mice, MCP-1 knockout mice, dominant-negative mutant gene delivery, metabolic phenotyping\",\n      \"pmids\": [\"16691291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of adipocyte- vs. macrophage-derived CCL2 not separated\", \"Direct hepatic signaling targets of CCL2 in steatosis undefined\", \"Human genetic evidence for CCL2 in metabolic syndrome not provided\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"iPLA2β and cPLA2α were identified as spatially segregated effectors downstream of CCL2-induced chemotaxis: iPLA2β localizes to the pseudopod and controls directionality and actin polymerization, while cPLA2α at the ER controls migration speed, explaining how a single chemokine generates multi-component migratory responses.\",\n      \"evidence\": \"Antisense knockdown, subcellular localization imaging, actin polymerization assay, adoptive transfer migration in vivo\",\n      \"pmids\": [\"18208975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lipid products mediating each PLA2 branch not identified\", \"How CCR2 differentially activates iPLA2β vs. cPLA2α unknown\", \"Whether this mechanism applies to other CC chemokine receptors untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"CCL2 was placed in neural circuitry: TNF-α/JNK induces astrocytic CCL2, which activates ERK in spinal dorsal horn neurons, enhances excitatory postsynaptic currents, and potentiates NMDA/AMPA responses, defining a glial-to-neuronal CCL2 signaling axis in neuropathic pain central sensitization.\",\n      \"evidence\": \"JNK inhibitors, spinal nerve ligation model, intrathecal MCP-1 neutralizing antibody, patch-clamp electrophysiology\",\n      \"pmids\": [\"19339605\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct neuronal receptor mediating synaptic potentiation not confirmed as CCR2 vs. alternative\", \"Whether astrocytic CCL2 acts presynaptically or postsynaptically not resolved\", \"Contribution relative to other pain chemokines not quantified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CCL2 was shown to be subject to reactive nitrogen species–mediated nitration in the tumor microenvironment, which abolishes T-cell recruitment into tumor cores; pharmacological inhibition of nitration restored CTL infiltration, identifying post-translational nitration as a tumor immune evasion mechanism.\",\n      \"evidence\": \"RNS detection, chemokine nitration biochemistry, T-cell trafficking assays, pharmacological inhibition in mouse and human tumors\",\n      \"pmids\": [\"21930770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific tyrosine residue(s) nitrated not mapped\", \"Whether nitrated CCL2 acquires gain-of-function activities unknown\", \"Generalizability to other chemokines in the tumor microenvironment not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CCL2 was causally linked to breast cancer metastasis: tumor/stromal CCL2 recruits CCR2+Ly-6C+ inflammatory monocytes to pulmonary metastatic sites, and these monocytes promote tumor cell extravasation through VEGF production, defining a CCL2→CCR2→VEGF→extravasation metastatic axis.\",\n      \"evidence\": \"CCL2-knockout mice, antibody blockade, bone marrow chimeras, monocyte depletion, in vivo metastasis model\",\n      \"pmids\": [\"21654748\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether tumor cells co-opt additional CCL2-independent monocyte recruitment pathways not assessed\", \"Precise mechanism by which monocyte-derived VEGF promotes extravasation not defined\", \"Clinical relevance of CCL2 blockade withdrawal (rebound effect) not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"IκBζ was identified as a direct transcriptional coactivator of Ccl2 by ChIP, linking NF-κB to epigenetic activation: IκBζ binding enables H3K4 trimethylation at the Ccl2 promoter, and IκBζ-deficient macrophages show impaired CCL2 secretion and monocyte recruitment in vivo.\",\n      \"evidence\": \"IκBζ-knockout macrophages, ChIP for IκBζ and H3K4me3, peritonitis model, ELISA\",\n      \"pmids\": [\"23547114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methyltransferase recruited by IκBζ not identified\", \"Whether IκBζ cooperates with Sp1 at the proximal promoter untested\", \"Kinetics of epigenetic mark deposition relative to transcription initiation unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A senescence-associated feed-forward loop was defined: secreted CCL2 activates CCR2→ROS→p38→p53/p21 in mesenchymal stromal cells, and activated p53 further increases CCL2 transcription; BMI1 was identified as an epigenetic repressor that silences CCL2 via H2AK119Ub, with BMI1 decline during senescence derepressing CCL2.\",\n      \"evidence\": \"CCR2 knockdown, p38/MAPK/p53 inhibitors, ChIP for BMI1 and H2AK119Ub, ROS measurement\",\n      \"pmids\": [\"26573462\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BMI1 loss is a cause or consequence of senescence initiation not fully resolved\", \"Quantitative contribution of autocrine vs. paracrine CCL2 loop not measured\", \"Whether this loop operates in epithelial senescence unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Hepatocyte-specific CCL2 was found to be transcriptionally driven by Notch signaling through a conserved RBPJκ binding site in the Ccl2 promoter; hepatocyte-specific Ccl2 knockout reduced monocyte-derived macrophage infiltration and liver fibrosis in NASH, directly linking cell-type-specific CCL2 production to metabolic liver disease.\",\n      \"evidence\": \"Hepatocyte-specific Ccl2 knockout, Notch gain-of-function mice, RBPJκ promoter analysis, CCR2 inhibitor rescue, liver fibrosis quantification\",\n      \"pmids\": [\"36752206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Notch-driven CCL2 operates in other parenchymal cell types unknown\", \"Interaction between RBPJκ and NF-κB/Sp1 on the CCL2 promoter not characterized\", \"Therapeutic window for CCR2 inhibition in human NASH not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Despite extensive characterization, the full structural basis of CCL2–CCR2 activation (including the role of CCL2 oligomerization on GAGs in vivo), the identity of the non-CCR2 receptor mediating fibroblast transdifferentiation, and the quantitative contribution of individual cell-type-specific CCL2 sources across disease contexts remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of the CCL2–CCR2 signaling complex in a lipid bilayer\", \"Non-CCR2 receptor on fibroblasts not molecularly identified\", \"Systems-level quantification of tissue-specific CCL2 sources in vivo lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 6, 16]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 5, 7, 8, 16, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 6, 11, 16, 17, 18, 22, 23, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 14, 25, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 16, 17, 18, 27]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 20, 25, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR2\",\n      \"MMP1\",\n      \"MMP3\",\n      \"NFKB1\",\n      \"SP1\",\n      \"NFKBIZ\",\n      \"BMI1\",\n      \"ATF4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}